286 results on '"Codreanu, Catalin"'
Search Results
2. Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment
- Author
-
Ørnbjerg, Lykke Midtbøll, Brahe, Cecilie Heegaard, Linde, Louise, Jacobsson, Lennart, Nissen, Michael J., Kristianslund, Eirik Klami, Santos, Maria José, Nordström, Dan, Rotar, Ziga, Gudbjornsson, Bjorn, Onen, Fatos, Codreanu, Catalin, Lindström, Ulf, Möller, Burkhard, Kvien, Tore K., Barcelos, Anabela, Eklund, Kari K., Tomšič, Matija, Love, Thorvardur Jon, Can, Gercek, Ionescu, Ruxandra, Loft, Anne Gitte, Mann, Herman, Pavelka, Karel, van de Sande, Marleen, van der Horst-Bruinsma, I.E., Suarez, Manuel Pombo, Sánchez-Piedra, Carlos, Macfarlane, Gary J., Iannone, Florenzo, Michelsen, Brigitte, Hyldstrup, Lise Hejl, Krogh, Niels Steen, Østergaard, Mikkel, and Hetland, Merete Lund
- Published
- 2024
- Full Text
- View/download PDF
3. Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration
- Author
-
Linde, Louise, Ørnbjerg, Lykke M., Rasmussen, Simon H., Love, Thorvardur Jon, Loft, Anne Gitte, Závada, Jakub, Vencovský, Jiří, Laas, Karin, Nordstrom, Dan, Sokka-Isler, Tuulikki, Gudbjornsson, Bjorn, Gröndal, Gerdur, Iannone, Florenzo, Ramonda, Roberta, Hellamand, Pasoon, Kristianslund, Eirik K., Kvien, Tore K., Rodrigues, Ana M., Santos, Maria J., Codreanu, Catalin, Rotar, Ziga, Tomšič, Matija, Castrejon, Isabel, Díaz-Gonzáles, Federico, Di Giuseppe, Daniela, Ljung, Lotta, Nissen, Michael J., Ciurea, Adrian, Macfarlane, Gary J., Heddle, Maureen, Glintborg, Bente, Østergaard, Mikkel, and Hetland, Merete L.
- Published
- 2023
- Full Text
- View/download PDF
4. Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies
- Author
-
Lauper, Kim, Mongin, Denis, Bergstra, Sytske Anne, Choquette, Denis, Codreanu, Catalin, Gottenberg, Jacques-Eric, Kubo, Satoshi, Hetland, Merete Lund, Iannone, Florenzo, Kristianslund, Eirik K., Kvien, Tore K., Lukina, Galina, Mariette, Xavier, Nordström, Dan C., Pavelka, Karel, Pombo-Suarez, Manuel, Rotar, Ziga, Santos, Maria J., Tanaka, Yoshiya, Turesson, Carl, Courvoisier, Delphine S., Finckh, Axel, and Gabay, Cem
- Published
- 2024
- Full Text
- View/download PDF
5. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
- Author
-
Michelsen, Brigitte, Østergaard, Mikkel, Nissen, Michael John, Ciurea, Adrian, Möller, Burkhard, Ørnbjerg, Lykke Midtbøll, Zavada, Jakub, Glintborg, Bente, MacDonald, Alan, Laas, Karin, Nordström, Dan, Gudbjornsson, Bjorn, Iannone, Florenzo, Hellmand, Pasoon, Kvien, Tore Kristian, Rodrigues, Ana Maria, Codreanu, Catalin, Rotar, Ziga, Castrejón Fernández, Isabel, Wallman, Johan Karlsson, Vencovsky, Jiri, Loft, Anne Gitte, Heddle, Maureen, Vorobjov, Sigrid, Hokkanen, Anna-Mari, Gröndal, Gerdur, Sebastiani, Marco, van de Sande, Marleen, Kristianslund, Eirik Klami, Santos, Maria José, Mogosan, Corina, Tomsic, Matija, Díaz-González, Federico, Di Giuseppe, Daniela, and Hetland, Merete Lund
- Published
- 2023
- Full Text
- View/download PDF
6. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration
- Author
-
Ørnbjerg, Lykke M., Linde, Louise, Georgiadis, Stylianos, Rasmussen, Simon H., Lindström, Ulf, Askling, Johan, Michelsen, Brigitte, Giuseppe, Daniela Di, Wallman, Johan K., Pavelka, Karel, Závada, Jakub, Nissen, Michael J., Jones, Gareth T., Relas, Heikki, Pirilä, Laura, Tomšič, Matija, Rotar, Ziga, Geirsson, Arni Jon, Gudbjornsson, Bjorn, Kristianslund, Eirik K., van sder Horst-Bruinsma, Irene, Loft, Anne Gitte, Laas, Karin, Iannone, Florenzo, Corrado, Addolorata, Ciurea, Adrian, Santos, Maria J., Santos, Helena, Codreanu, Catalin, Akkoc, Nurullah, Gunduz, Ozgul S., Glintborg, Bente, Østergaard, Mikkel, and Hetland, Merete Lund
- Published
- 2022
- Full Text
- View/download PDF
7. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
- Author
-
Ørnbjerg, Lykke M., Rugbjerg, Kathrine, Georgiadis, Stylianos, Rasmussen, Simon H., Jacobsson, Lennart, Loft, Anne G., Iannone, Florenzo, Fagerli, Karen M., Vencovsky, Jiri, Santos, Maria J., Möller, Burkhard, Pombo-Suarez, Manuel, Rotar, Ziga, Gudbjornsson, Bjorn, Cefle, Ayse, Eklund, Kari, Codreanu, Catalin, Jones, Gareth, van der Sande, Marleen, Wallman, Johan K., Sebastiani, Marco, Michelsen, Brigitte, Závada, Jakub, Nissen, Michael J., Sanchez-Piedra, Carlos, Tomšič, Matija, Love, Thorvardur J., Relas, Heikki, Mogosan, Corina, Hetland, Merete L., Østergaard, Mikkel, Ørnbjerg, Lykke M., Rugbjerg, Kathrine, Georgiadis, Stylianos, Rasmussen, Simon H., Jacobsson, Lennart, Loft, Anne G., Iannone, Florenzo, Fagerli, Karen M., Vencovsky, Jiri, Santos, Maria J., Möller, Burkhard, Pombo-Suarez, Manuel, Rotar, Ziga, Gudbjornsson, Bjorn, Cefle, Ayse, Eklund, Kari, Codreanu, Catalin, Jones, Gareth, van der Sande, Marleen, Wallman, Johan K., Sebastiani, Marco, Michelsen, Brigitte, Závada, Jakub, Nissen, Michael J., Sanchez-Piedra, Carlos, Tomšič, Matija, Love, Thorvardur J., Relas, Heikki, Mogosan, Corina, Hetland, Merete L., and Østergaard, Mikkel
- Abstract
Objective To evaluate patient-reported outcomes (PROs) after initiation of tumor necrosis factor inhibitor (TNFi) treatment in European real-world patients with psoriatic arthritis (PsA). Further, to investigate PRO remission rates across treatment courses, registries, disease duration, sex, and age at disease onset. Methods Visual analog scale or numerical rating scale scores for pain, fatigue, patient global assessment (PtGA), and the Health Assessment Questionnaire–Disability Index (HAQ-DI) from 12,262 patients with PsA initiating a TNFi in 13 registries were pooled. PRO remission rates (pain ≤ 1, fatigue ≤ 2, PtGA ≤ 2, and HAQ-DI ≤ 0.5) were calculated for patients still on the treatment. Results For the first TNFi, median pain score was reduced by approximately 50%, from 6 to 3, 3, and 2; as were fatigue scores, from 6 to 4, 4, and 3; PtGA scores, from 6 to 3, 3, and 2; and HAQ-DI scores, from 0.9 to 0.5, 0.5, and 0.4 at baseline, 6, 12, and 24 months, respectively. Six-month Lund Efficacy Index (LUNDEX)–adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 24%, 31%, 36%, and 43% (first TNFi); 14%, 19%, 23%, and 29% (second TNFi); and 9%, 14%, 17%, and 20% (third TNFi), respectively. For biologic-naïve patients with disease duration < 5 years, 6-month LUNDEX-adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 22%, 28%, 33%, and 42%, respectively. Corresponding rates for patients with disease duration > 10 years were 27%, 32%, 41%, and 43%, respectively. Remission rates were 33%, 40%, 45%, and 56% for men and 17%, 23%, 24%, and 32% for women, respectively. For patients aged < 45 years at diagnosis, 6-month LUNDEX-adjusted remission rate for pain was 29% vs 18% for patients ≥ 45 years. Conclusion In 12,262 biologic-naïve patients with PsA, 6 months of treatment with a TNFi reduced pain by approximately 50%. Marked differences in PRO remission rates across treatment courses, registries, di, Objective. To evaluate patient-reported outcomes (PROs) after initiation of tumor necrosis factor inhibitor (TNFi) treatment in European real-world patients with psoriatic arthritis (PsA). Further, to investigate PRO remission rates across treatment courses, registries, disease duration, sex, and age at disease onset. Methods. Visual analog scale or numerical rating scale scores for pain, fatigue, patient global assessment (PtGA), and the Health Assessment Questionnaire–Disability Index (HAQ-DI) from 12,262 patients with PsA initiating a TNFi in 13 registries were pooled. PRO remission rates (pain ≤ 1, fatigue ≤ 2, PtGA ≤ 2, and HAQ-DI ≤ 0.5) were calculated for patients still on the treatment. Results. For the first TNFi, median pain score was reduced by approximately 50%, from 6 to 3, 3, and 2; as were fatigue scores, from 6 to 4, 4, and 3; PtGA scores, from 6 to 3, 3, and 2; and HAQ-DI scores, from 0.9 to 0.5, 0.5, and 0.4 at baseline, 6, 12, and 24 months, respectively. Six-month Lund Efficacy Index (LUNDEX)–adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 24%, 31%, 36%, and 43% (first TNFi); 14%, 19%, 23%, and 29% (second TNFi); and 9%, 14%, 17%, and 20% (third TNFi), respectively. For biologic-naïve patients with disease duration < 5 years, 6-month LUNDEX-adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 22%, 28%, 33%, and 42%, respectively. Corresponding rates for patients with disease duration > 10 years were 27%, 32%, 41%, and 43%, respectively. Remission rates were 33%, 40%, 45%, and 56% for men and 17%, 23%, 24%, and 32% for women, respectively. For patients aged < 45 years at diagnosis, 6-month LUNDEX-adjusted remission rate for pain was 29% vs 18% for patients ≥ 45 years. Conclusion. In 12,262 biologic-naïve patients with PsA, 6 months of treatment with a TNFi reduced pain by approximately 50%. Marked differences in PRO remission rates across treatment courses, registries, disease duration, sex
- Published
- 2024
8. Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis:Results From the European Spondyloarthritis Research Collaboration Network
- Author
-
Hellamand, Pasoon, van de Sande, Marleen G.H., Ørnbjerg, Lykke M., Klausch, Thomas, Eklund, Kari K., Relas, Heikki, Santos, Maria J., Vieira-Sousa, Elsa, Loft, Anne G., Glintborg, Bente, Østergaard, Mikkel, Lindström, Ulf, Wallman, Johan K., Michelsen, Brigitte, Fagerli, Karen M., Castrejón, Isabel, Gudbjornsson, Bjorn, Love, Thorvardur J., Vencovský, Jiří, Nekvindová, Lucie, Rotar, Žiga, Tomšič, Matija, Díaz-González, Federico, Kenar, Gökçe, Tuğsal, Handan Y., Iannone, Florenzo, Ramonda, Roberta, Codreanu, Catalin, Mogosan, Corina, Nissen, Michael J., Möller, Burkhard, Hetland, Merete L., van der Horst-Bruinsma, Irene E., Hellamand, Pasoon, van de Sande, Marleen G.H., Ørnbjerg, Lykke M., Klausch, Thomas, Eklund, Kari K., Relas, Heikki, Santos, Maria J., Vieira-Sousa, Elsa, Loft, Anne G., Glintborg, Bente, Østergaard, Mikkel, Lindström, Ulf, Wallman, Johan K., Michelsen, Brigitte, Fagerli, Karen M., Castrejón, Isabel, Gudbjornsson, Bjorn, Love, Thorvardur J., Vencovský, Jiří, Nekvindová, Lucie, Rotar, Žiga, Tomšič, Matija, Díaz-González, Federico, Kenar, Gökçe, Tuğsal, Handan Y., Iannone, Florenzo, Ramonda, Roberta, Codreanu, Catalin, Mogosan, Corina, Nissen, Michael J., Möller, Burkhard, Hetland, Merete L., and van der Horst-Bruinsma, Irene E.
- Abstract
Objective Women with psoriatic arthritis (PsA) may have reduced tumor necrosis factor inhibitor (TNFi) effectiveness compared to men. We examined sex differences in treatment response and retention rates during 24 months of follow-up among patients with PsA initiating their first TNFi. Methods Data from patients with PsA across 13 European Spondyloarthritis Research Collaboration Network registries starting their first TNFi were pooled. Logistic regression was used to analyze the association between sex and treatment response using low disease activity (LDA) according to the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) (<3.2) at six months as the primary outcome. Analyses were adjusted for age, country, conventional synthetic disease-modifying antirheumatic drug treatment, and TNFi start year. Retention rates were explored using the Kaplan–Meier estimator. Results We analyzed the treatment response of 7,679 patients with PsA (50% women) with available data on LDA at six months. At baseline, women and men had similar characteristics, including mean DAS28-CRP (women vs men, 4.4 [SD 1.2] vs 4.2 [SD 1.2]), though patient-reported outcome measures were worse in women. At six months, 64% of women and 78% of men had LDA (relative risk [RR] 0.82; 95% confidence interval [CI] 0.80–0.84). This difference was similar after adjustment (RR 0.83; 95% CI 0.81–0.85). TNFi retention rates were evaluated in 17,842 patients with PsA. Women had significantly lower retention rates than men at all time points (women 79%, 64%, and 50% vs men 88%, 77%, and 64% at 6, 12, and 24 months, respectively). Conclusion Despite comparable disease characteristics at baseline, women with PsA have reduced treatment response and retention rates to their first TNFi, highlighting the need to consider sex differences in PsA research and management., Objective: Women with psoriatic arthritis (PsA) may have reduced tumor necrosis factor inhibitor (TNFi) effectiveness compared to men. We examined sex differences in treatment response and retention rates during 24 months of follow-up among patients with PsA initiating their first TNFi. Methods: Data from patients with PsA across 13 European Spondyloarthritis Research Collaboration Network registries starting their first TNFi were pooled. Logistic regression was used to analyze the association between sex and treatment response using low disease activity (LDA) according to the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) (<3.2) at six months as the primary outcome. Analyses were adjusted for age, country, conventional synthetic disease-modifying antirheumatic drug treatment, and TNFi start year. Retention rates were explored using the Kaplan–Meier estimator. Results: We analyzed the treatment response of 7,679 patients with PsA (50% women) with available data on LDA at six months. At baseline, women and men had similar characteristics, including mean DAS28-CRP (women vs men, 4.4 [SD 1.2] vs 4.2 [SD 1.2]), though patient-reported outcome measures were worse in women. At six months, 64% of women and 78% of men had LDA (relative risk [RR] 0.82; 95% confidence interval [CI] 0.80–0.84). This difference was similar after adjustment (RR 0.83; 95% CI 0.81–0.85). TNFi retention rates were evaluated in 17,842 patients with PsA. Women had significantly lower retention rates than men at all time points (women 79%, 64%, and 50% vs men 88%, 77%, and 64% at 6, 12, and 24 months, respectively). Conclusion: Despite comparable disease characteristics at baseline, women with PsA have reduced treatment response and retention rates to their first TNFi, highlighting the need to consider sex differences in PsA research and management.
- Published
- 2024
9. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor:results from 13 European registries
- Author
-
Linde, Louise, Ørnbjerg, Lykke M., Georgiadis, Stylianos, Rasmussen, Simon H., Lindström, Ulf, Askling, Johan, Michelsen, Brigitte, Di Giuseppe, Daniela, Wallman, Johan K., Gudbjornsson, Bjorn, Love, Thorvardur Jon, Nordström, Dan C., Yli-Kerttula, Timo, Nekvindová, Lucie, Vencovský, Jiří, Iannone, Florenzo, Cauli, Alberto, Loft, Anne Gitte, Glintborg, Bente, Laas, Karin, Rotar, Ziga, Tomšič, Matija, MacFarlane, Gary J., Möller, Burkhard, Van De Sande, Marleen, Codreanu, Catalin, Nissen, Michael J., Birlik, Merih, Erten, Sukran, Santos, Maria J., Vieira-Sousa, Elsa, Hetland, Merete L., Østergaard, Mikkel, Linde, Louise, Ørnbjerg, Lykke M., Georgiadis, Stylianos, Rasmussen, Simon H., Lindström, Ulf, Askling, Johan, Michelsen, Brigitte, Di Giuseppe, Daniela, Wallman, Johan K., Gudbjornsson, Bjorn, Love, Thorvardur Jon, Nordström, Dan C., Yli-Kerttula, Timo, Nekvindová, Lucie, Vencovský, Jiří, Iannone, Florenzo, Cauli, Alberto, Loft, Anne Gitte, Glintborg, Bente, Laas, Karin, Rotar, Ziga, Tomšič, Matija, MacFarlane, Gary J., Möller, Burkhard, Van De Sande, Marleen, Codreanu, Catalin, Nissen, Michael J., Birlik, Merih, Erten, Sukran, Santos, Maria J., Vieira-Sousa, Elsa, Hetland, Merete L., and Østergaard, Mikkel
- Abstract
Objectives In bio-naïve patients with PsA initiating a TNF inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries. Methods Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes were defined as common predictors. Results In the pooled cohort (n = 13 369), 6-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n = 6954, n = 5275 and n = 13 369, respectively). Five common baseline predictors of remission, moderate response and 12-month drug retention were identified across all three outcomes. The odds ratios (95% CIs) for DAPSA28 remission were: age, per year: 0.97 (0.96–0.98); disease duration, years (<2 years as reference): 2–3 years: 1.20 (0.89–1.60), 4–9 years: 1.42 (1.09–1.84), ≥10 years: 1.66 (1.26–2.20); men vs women: 1.85 (1.54–2.23); CRP of >10 vs ≤10 mg/l: 1.52 (1.22–1.89) and 1 mm increase in patient fatigue score: 0.99 (0.98–0.99). Conclusion Baseline predictors of remission, response and adherence to TNFi therapy were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalizable from country level to disease level., Objectives: In bio-naïve patients with PsA initiating a TNF inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries. Methods: Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes were defined as common predictors. Results: In the pooled cohort (n=13 369), 6-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n=6954, n=5275 and n=13 369, respectively). Five common baseline predictors of remission, moderate response and 12-month drug retention were identified across all three outcomes. The odds ratios (95% CIs) for DAPSA28 remission were: age, per year: 0.97 (0.96-0.98); disease duration, years (<2 years as reference): 2-3 years: 1.20 (0.89-1.60), 4-9 years: 1.42 (1.09-1.84), ≥10 years: 1.66 (1.26-2.20); men vs women: 1.85 (1.54-2.23); CRP of >10 vs ≤10 mg/l: 1.52 (1.22-1.89) and 1mm increase in patient fatigue score: 0.99 (0.98-0.99). Conclusion: Baseline predictors of remission, response and adherence to TNFi therapy were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalizable from country level to disease level.
- Published
- 2024
10. Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept:Results from the international TOCERRA and PANABA observational collaborative studies
- Author
-
Lauper, Kim, Mongin, Denis, Bergstra, Sytske Anne, Choquette, Denis, Codreanu, Catalin, Gottenberg, Jacques Eric, Kubo, Satoshi, Hetland, Merete Lund, Iannone, Florenzo, Kristianslund, Eirik K., Kvien, Tore K., Lukina, Galina, Mariette, Xavier, Nordström, Dan C., Pavelka, Karel, Pombo-Suarez, Manuel, Rotar, Ziga, Santos, Maria J., Tanaka, Yoshiya, Turesson, Carl, Courvoisier, Delphine S., Finckh, Axel, Gabay, Cem, Lauper, Kim, Mongin, Denis, Bergstra, Sytske Anne, Choquette, Denis, Codreanu, Catalin, Gottenberg, Jacques Eric, Kubo, Satoshi, Hetland, Merete Lund, Iannone, Florenzo, Kristianslund, Eirik K., Kvien, Tore K., Lukina, Galina, Mariette, Xavier, Nordström, Dan C., Pavelka, Karel, Pombo-Suarez, Manuel, Rotar, Ziga, Santos, Maria J., Tanaka, Yoshiya, Turesson, Carl, Courvoisier, Delphine S., Finckh, Axel, and Gabay, Cem
- Abstract
Objective To evaluate and compare the use of oral glucocorticoids with three classes of bDMARDs in patients with rheumatoid arthritis (RA). Methods We included patients from 13 observational registries treated with a TNF-inhibitor, abatacept or tocilizumab and with available information on the use of oral glucocorticoids. The main outcome was oral glucocorticoid withdrawal. A McNemar test was used to analyse the change in the use of glucocorticoids after 1 year. Kaplan-Meier estimates and Cox regressions, adjusted for patient, treatment, and disease characteristics, were used to evaluate glucocorticoid discontinuation in patients with glucocorticoids at baseline. Because of heterogeneity, analyses were done by registers and pooled using random-effects meta-analysis. Results A total of 12,334 participants treated with TNF-inhibitors, 2100 with tocilizumab and 3229 with abatacept were included. At one-year, oral glucocorticoid use decreased in all treatment groups (odds ratio for stopping vs. starting of 2.19 [95% CI 1.58; 3.04] for TNF-inhibitors, 2.46 [1.39; 4.35] for tocilizumab; 1.73 [1.25; 2.21] for abatacept). Median time to glucocorticoid withdrawal was ≈2 years or more in most countries, with a gradual decrease over time. Compared to TNF-inhibitors, crude hazard ratios of glucocorticoid discontinuation were 0.65[0.48–0.87] for abatacept, and 1.04 [0.76–1.43] for tocilizumab, and adjusted hazard ratios were 1.1 [0.83–1.47] for abatacept, and 1.30 [0.96–1.78] for tocilizumab. Conclusion After initiation of a bDMARD, glucocorticoid use decreased similarly in all treatment groups. However, glucocorticoid withdrawal was much slower than advocated by current international guidelines. More effort should be devoted to glucocorticoid tapering when low disease activity is achieved., Objective: To evaluate and compare the use of oral glucocorticoids with three classes of bDMARDs in patients with rheumatoid arthritis (RA). Methods: We included patients from 13 observational registries treated with a TNF-inhibitor, abatacept or tocilizumab and with available information on the use of oral glucocorticoids. The main outcome was oral glucocorticoid withdrawal. A McNemar test was used to analyse the change in the use of glucocorticoids after 1 year. Kaplan-Meier estimates and Cox regressions, adjusted for patient, treatment, and disease characteristics, were used to evaluate glucocorticoid discontinuation in patients with glucocorticoids at baseline. Because of heterogeneity, analyses were done by registers and pooled using random-effects meta-analysis. Results: A total of 12,334 participants treated with TNF-inhibitors, 2100 with tocilizumab and 3229 with abatacept were included. At one-year, oral glucocorticoid use decreased in all treatment groups (odds ratio for stopping vs. starting of 2.19 [95% CI 1.58; 3.04] for TNF-inhibitors, 2.46 [1.39; 4.35] for tocilizumab; 1.73 [1.25; 2.21] for abatacept). Median time to glucocorticoid withdrawal was ≈2 years or more in most countries, with a gradual decrease over time. Compared to TNF-inhibitors, crude hazard ratios of glucocorticoid discontinuation were 0.65[0.48–0.87] for abatacept, and 1.04 [0.76–1.43] for tocilizumab, and adjusted hazard ratios were 1.1 [0.83–1.47] for abatacept, and 1.30 [0.96–1.78] for tocilizumab. Conclusion: After initiation of a bDMARD, glucocorticoid use decreased similarly in all treatment groups. However, glucocorticoid withdrawal was much slower than advocated by current international guidelines. More effort should be devoted to glucocorticoid tapering when low disease activity is achieved.
- Published
- 2024
11. Sex Differences in the Effectiveness of First‐Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network
- Author
-
Hellamand, Pasoon, primary, van de Sande, Marleen G. H., additional, Ørnbjerg, Lykke M., additional, Klausch, Thomas, additional, Eklund, Kari K., additional, Relas, Heikki, additional, Santos, Maria J., additional, Vieira‐Sousa, Elsa, additional, Loft, Anne G., additional, Glintborg, Bente, additional, Østergaard, Mikkel, additional, Lindström, Ulf, additional, Wallman, Johan K., additional, Michelsen, Brigitte, additional, Fagerli, Karen M., additional, Castrejón, Isabel, additional, Gudbjornsson, Bjorn, additional, Love, Thorvardur J., additional, Vencovský, Jiří, additional, Nekvindová, Lucie, additional, Rotar, Žiga, additional, Tomšič, Matija, additional, Díaz‐González, Federico, additional, Kenar, Gökçe, additional, Tuğsal, Handan Y., additional, Iannone, Florenzo, additional, Ramonda, Roberta, additional, Codreanu, Catalin, additional, Mogosan, Corina, additional, Nissen, Michael J., additional, Möller, Burkhard, additional, Hetland, Merete L., additional, and van der Horst‐Bruinsma, Irene E., additional
- Published
- 2024
- Full Text
- View/download PDF
12. Correction: Agache et al. Nail Ultrasound in Psoriasis and Psoriatic Arthritis—A Narrative Review. Diagnostics 2023, 13, 2236
- Author
-
Agache, Mihaela, primary, Popescu, Claudiu C., additional, Enache, Luminita, additional, Dumitrescu, Bianca M., additional, and Codreanu, Catalin, additional
- Published
- 2024
- Full Text
- View/download PDF
13. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
- Author
-
Ørnbjerg, Lykke M., primary, Rugbjerg, Kathrine, additional, Georgiadis, Stylianos, additional, Rasmussen, Simon H., additional, Jacobsson, Lennart, additional, Loft, Anne G., additional, Iannone, Florenzo, additional, Fagerli, Karen M., additional, Vencovsky, Jiri, additional, Santos, Maria J., additional, Möller, Burkhard, additional, Pombo-Suarez, Manuel, additional, Rotar, Ziga, additional, Gudbjornsson, Bjorn, additional, Cefle, Ayse, additional, Eklund, Kari, additional, Codreanu, Catalin, additional, Jones, Gareth, additional, van der Sande, Marleen, additional, Wallman, Johan K., additional, Sebastiani, Marco, additional, Michelsen, Brigitte, additional, Závada, Jakub, additional, Nissen, Michael J., additional, Sanchez-Piedra, Carlos, additional, Tomšič, Matija, additional, Love, Thorvardur J., additional, Relas, Heikki, additional, Mogosan, Corina, additional, Hetland, Merete L., additional, and Østergaard, Mikkel, additional
- Published
- 2024
- Full Text
- View/download PDF
14. Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
- Author
-
Michelsen, Brigitte, Georgiadis, Stylianos, Di Giuseppe, Daniela, Loft, Anne G., Nissen, Michael J., Iannone, Florenzo, Pombo‐Suarez, Manuel, Mann, Herman, Rotar, Ziga, Eklund, Kari K., Kvien, Tore K., Santos, Maria J., Gudbjornsson, Bjorn, Codreanu, Catalin, Yilmaz, Sema, Wallman, Johan K., Brahe, Cecilie H., Möller, Burkhard, Favalli, Ennio G., Sánchez‐Piedra, Carlos, Nekvindova, Lucie, Tomsic, Matija, Trokovic, Nina, Kristianslund, Eirik K., Santos, Helena, Löve, Thorvardur J., Ionescu, Ruxandra, Pehlivan, Yavuz, Jones, Gareth T., van der Horst‐Bruinsma, Irene, Ørnbjerg, Lykke M., Østergaard, Mikkel, and Hetland, Merete L.
- Published
- 2022
- Full Text
- View/download PDF
15. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
- Author
-
Aymon, Romain, Mongin, Denis, Bergstra, Sytske Anne, Choquette, Denis, Codreanu, Catalin, De Cock, Diederik, Dreyer, Lene, Elkayam, Ori, Huschek, Doreen, Hyrich, Kimme L., Iannone, Florenzo, Inanc, Nevsun, Kearsley-Fleet, Lianne, KOCA, Suleyman Serdar, Kvien, Tore K., Leeb, Burkhard F., Lukina, Galina, Nordström, Dan C., Pavelka, Karel, and Pombo-Suarez, Manuel
- Published
- 2024
- Full Text
- View/download PDF
16. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study)
- Author
-
Aymon, Romain, primary, Mongin, Denis, additional, Bergstra, Sytske Anne, additional, Choquette, Denis, additional, Codreanu, Catalin, additional, De Cock, Diederik, additional, Dreyer, Lene, additional, Elkayam, Ori, additional, Huschek, Doreen, additional, Hyrich, Kimme L, additional, Iannone, Florenzo, additional, Inanc, Nevsun, additional, Kearsley-Fleet, Lianne, additional, KOCA, Suleyman Serdar, additional, Kvien, Tore K, additional, Leeb, Burkhard F, additional, Lukina, Galina, additional, Nordström, Dan C, additional, Pavelka, Karel, additional, Pombo-Suarez, Manuel, additional, Rodrigues, Ana, additional, Rotar, Ziga, additional, Strangfeld, Anja, additional, Verschueren, Patrick, additional, Westermann, Rasmus, additional, Zavada, Jakub, additional, Courvoisier, Delphine Sophie, additional, Finckh, Axel, additional, and Lauper, Kim, additional
- Published
- 2023
- Full Text
- View/download PDF
17. Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis: results from the EuroSpA Research Collaboration Network
- Author
-
Hellamand, Pasoon, primary, van de Sande, Marleen, additional, Ørnbjerg, Lykke MIdtbøll, additional, Klausch, Thomas, additional, Nurmohamed, Michael T, additional, van Vollenhoven, Ronald F, additional, Nordström, Dan, additional, Hokkanen, Anna Mari, additional, Santos, Maria Jose, additional, Vieira-Sousa, Elsa, additional, Loft, Anne G, additional, Glintborg, Bente, additional, Hetland, Merete Lund, additional, Lindström, Ulf, additional, Wallman, Johan K, additional, Michelsen, Brigitte, additional, Klami Kristianslund, Eirik, additional, Ciurea, Adrian, additional, Nissen, Michael S, additional, Codreanu, Catalin, additional, Mogosan, Corina, additional, Macfarlane, Gary J, additional, Rotariu, Ovidiu, additional, Rotar, Ziga, additional, Tomšič, Matija, additional, Castrejon, Isabel, additional, Otero-Varela, Lucia, additional, Gudbjornsson, Bjorn, additional, Geirsson, Arni Jon, additional, Vencovský, Jiří, additional, Pavelka, Karel, additional, Gulle, Semih, additional, Zengin, Berrin, additional, Iannone, Florenzo, additional, Foti, Rosario, additional, Ostergaard, Mikkel, additional, and van der Horst-Bruinsma, Irene, additional
- Published
- 2023
- Full Text
- View/download PDF
18. From Pathogenesis to Treatment—New Perspectives in Rheumatology
- Author
-
Rezus, Elena, primary and Codreanu, Catalin, additional
- Published
- 2023
- Full Text
- View/download PDF
19. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
- Author
-
Mautalén, Carlos Alfredo, Man, Zulema, Zanchetta, Jose Ruben, Magaril, Clelia Haydee, Sambrook, Philip, Reginster, Jean-Yves, Geusens, Piet, Goemaere, Stefan, Albergaria, Ben Hur, Zerbini, Cristiano Augusto de Freitas, Castro, Marise Lazaretti, Gregorio, Luiz Henrique, Stoilov, Rumen, Borissova, Anna-Maria I, Hristozov, Kiril Hristov, Temelkova, Nataliya L, Daskalova, Ivona Kirilova, Kuzmanova, Stefka Ivanova, Yaneva-Bichovska, Daniela, Batalov, Anastas Zgurov, Riedemann, Pablo, Rodriguez Portales, José Adolfo, Tang, Hai, Zhu, hanmin, Zhang, Zhenlin, Chao, Aijun, Hu, Yali, Liu, Zhiming, Lu, Juming, Qiu, Mingcai, Gao, Xin, Zhang, Shaofen, Xu, Ling, Xia, Weibo, Liao, Eryuan, Yang, Wenying, Wu, Wen, Dai, Kerong, Hu, Renming, Jaller, Juan Jose, Cabal, Francisco, Molina, José Fernando, Cure Cure, Carlos A, Yupanqui-Lozno, Hernan, Chalem, Philippe, Londono, John, Abello, Mauricio, Tobias, Edgardo D, Otero, William, Nikolic, Tatjana, Miskic, Blazenka, Stepan, Jan, Vyskocil, Vaclav, Novosad, Libor, Slesinger, Jan, Novosad, Pavel, Vlckova, Erika, Bortlik, Ladislav, Dokoupilova, Eva, Hala, Tomas, Jensen, Jens-Erik Beck, Brixen, Kim Torsten, Langdahl, Bente Lomholt, Schwarz, Peter, Eskildsen, Peter Claes, Eiken, Pia Agnete, Hermann, Anne Pernille, Gram, Jeppe, Schou, Maiken Brix, Alexandersen, Peter, Nedergaard, Bettina, Mejía, Dolores Magdalena, Estrella De Henriquez, Lourdes, Páez, Norka, Velazco, Casimiro, Valter, Ivo, Vahula, Kadri-Liina, Kull, Ingrid, Maasalu, Katre, Chapurlat, Roland, Fardellone, Patrice, Benhamou, Claude Laurent, Roux, Christian, Weryha, Georges, Herkt, Volkmar, Martz, Rene, Nischik, Ruth, Spieler, Wolfgang, Contzen, Christel, Felsenberg, Dieter, Frieling, Isolde, Frahm, Eike, Briones, Henry, Sandoval, Boris, Barrios, Patricia, García, Abraham, Avendaño, Carlos, González, Magdalena, Guerra, Jeremías, Tuna, Maria, Díaz, Olga Marina, Samayoa, Eduardo, López, Edgar, Barrera, José Raúl, Palencia, Mainor, Cifuentes, Mayra, Alvarado, Georgina, López, Miriam, Chavez, Nilmo, Haase, Franklin, Rivera, Ruddy, González, Claudio, Tan, Kathryn, Leung, Ping Chung, Mandalam, Sheshadri, Pitale, Shailesh Umakant, Bantwal, Ganapathi, Ammini, Ariachery Chinamma, Shaikh, Shehla Sajid Akhta, Kanakatte Mylariah, Prasanna Kumar, Dharmalingam, Mala, Mukhopadhyay, Satinath, Jain, Arpit, Singh, Parminder, Shetty, Naresh, Sathyanarayana, Srikanta Shamanna, Shah, Nalini, Chadha, Manoj Dharam, Bhandankar, Rajendra, Velayutham, Kumaravel, Marwah, Sudha, John, Mathew, Sahay, Rakesh Kumar, Adami, Silvano, Nuti, Ranuccio, Bianchi, Gerolamo, Brandi, Maria Luisa, Minisola, Salvatore, Fiore, Carmelo Erio, Rubinacci, Alessandro, Miyajima, Hisayuki, Yamane, Hiroo, Nakatani, Yuji, Okamoto, Sumiaki, Kuroda, Koji, Fujimori, Motoaki, Itabashi, Akira, Katayama, Kuniaki, Nakajo, Satoru, Somekawa, Yoshiaki, Ohsawa, Yoshimitsu, Tajima, Wataru, Mizuno, Katsunori, Mori, Shigeru, Kanabuchi, Takato, Hashizume, Hiroyuki, Oka, Nobuyuki, Hamada, Kazutoshi, Yamaguchi, Motoi, Hirahara, Fumiki, Atobe, Masaaki, Ohtake, Yoshiharu, Ichikawa, Shuichi, Onishi, Tomoyuki, Matsumoto, Kou, Nakamura, Tetsuro, Shirasawa, Eishi, Katayama, Ko, Takahashi, Mitsugu, Oguma, Tadanori, Matsui, Hideo, Katoh, Yoshiharu, Shigenobu, Keiichi, Onishi, Tsutomu, Shibukawa, Masato, Ikeda, Satoshi, Osaka, Kazuhiro, Kanda, Ryosuke, Inobe, Yoshito, Shigenobu, Masaharu, Hasegawa, Morimasa, Yamaji, Tetsuo, Miyazaki, Yu, Ito, Takayasu, Nakamura, Eisuke, Nagai, Shinji, Lim, Sung-Kil, Chung, Yoon-Sok, Shin, Chan-Soo, Min, Yong-Ki, Kim, Ghi Su, Yoon, Hyun Koo, Kang, Moo-Il, Yang, Kyu-Hyun, Park, Hyoung Moo, Kim, In Joo, Chung, Dong Jin, Chung, Ho Yeon, Jaundzeikare, Sandra, Andersone, Dace, Medne, Agita, Yaghi, Yasser, Alekna, Vidmantas, Kasiulevicius, Vytautas, Purtokaite - Labutiniene, Irina, Krasauskiene, Aurelija, Varanaviciene, Jurate, Basijokiene, Vida, Abraitiene, Agne, Radzeviciene, Lina, Walliser, Jesus, García Hernández, Pedro Alberto, Araujo, Maria Frida, Avila Armengol, Hilario Ernesto, De la Peña, Pilar, Tamayo, Juan, Zazueta, Beatriz, Cons, Fidencio, Gilchrist, Nigel Leslie, Reid, Ian Reginald, Leikis, Robert, Jones, Peter, Singh, Joe Gragrath Pradeep, Halse, Johan Inge, Syversen, Unni, Høivik, Hans Olav, Øfjord, Erik Snorre, Gulseth, Hans Christian, Elle, Sigbjørn, Norheim, Paal Dag, Calvo Quiroz, Armando A., Cesar Augusto, Pastor A., León Portocarrero, Manuel Gustavo, Vidal Neira, Luis Fernando, Chavez, Jose, Garro Barrera, Boris, Kuroiwa Sampei, Rita, Luis Fernando, Bellatín V., Oquelis Cabredo, Rogger, Castillo, Sonia, Morales, Agustin Miguel G, Tan, Perry Pua, Leagogo, Liberato Antonio C, Jr., Wang, Edward HM, Li-Yu, Julie T, Sawicki, Andrzej Z, Stasiuk, Barbara, Kania, Grzegorz, Lorenc, Roman, Sidorowicz-Bialynicka, Anna, Szczepanski, Leszek, Franek, Edward, Filip, Rafal, Sekula, Jan, Blicharski, Tomasz, Leszczynski, Piotr, Sewerynek, Ewa, Miazgowski, Tomasz, Milewicz, Andrzej, Dabrowska, Magda, Romaszko, Jerzy, Pluskiewicz, Wojciech, Wojnowski, Lukasz, Codreanu, Catalin, Bolosiu, Horatiu, Ionescu, Ruxandra, Zosin, Ioana, Macovei, Liviu, Bojinca, Mihai, Radulescu, Florin, Pop, Simona, Sarbu, Adrian, Benevolenskaya, Lidia I, Nasonov, Evgeny L, Rozhinskaya, Lyudmila Ya, Oganov, Raphael G, Rodionova, Svetlana S, Shlyakhto, Eugeny Vladimirovich, Trofimov, Vasiliy, Zotkin, Eugeny G, Zazerskaya, Irina E, Grineva, Elena N, Ershova, Olga, Lesnyak, Olga, Ostroumova, Olga D, Malichenko, Svetlana B, Pikhlak, Eduard G, Pilyaev, Valery G, Raskina, Tatiana, Zonova, Elena V, Shirinsky, Valery S, Dimic, Aleksandar N, Cobeljic, Goran, Vujovic, Svetlana, Ellis, Graham Charlston, Lipschitz, Stanley, De Villiers, Tobias Johannes, De Weerd, Albert Jan, Vally, Tasneem, Trinder, Yvonne, Coetsee, Jacobus Ludewikus, Davis, Charles Pierre, Nayiager, Savithree, Hough, Frans Stephanus, Oelofse, Louis F, van der Walt, Eugene, Lombaard, Johannes Jurgens, Blignaut, Suzanne, Govind, Uttam, Fouche, Leon Frederik, Kruger, Dawid Stephanus, Dalmeyer, Johannes Paul, Ferreira, Mada M, Escudero-Contreras, Alejandro, Muñoz Torres, Manuel, Hawkins Carranza, Federico, Perez Castrillon, Jose Luis, García Meijide, Juan Antonio, Jodar Gimeno, Esteban, Palacios Gil-Antuñana, Santiago, de Teresa Parreno, Luis, Martín Mola, Emilio, Alvarez Sanchez, Carmen, Lippuner, Kurt, Tsai, Keh-Sung, Tu, Shih-Te, Chen, Jung-Fu, Lee, Oscar Kuang-Sheng, Hsu, Wen-Wei, Grygorieva, Natalia Viktorivna, Povoroznyuk, Vladyslav Volodymyrovych, Korzh, Mykola Oleksiiovych, Loskutov, Oleksandr Levgeniiovych, Chukov, Andriy Borysovych, Sarmiento, Rex, Thomas, Hawys, Donnachie, Hugh, Pavel-Knox, Irina, Shaw, Hilary, Hassanin, Hana, Abdulhakim, Essam Eldin Ahmed, Savani, Naren, Bachmann, Gloria A, Barrett-Connor, Elizabeth, Binkley, Neil C, Bone, Henry G, Brandon, Donald M, Checketts, Darin David, Fraser, Neil J, Watts, Nelson B, Geller, Steven A, Gimbel, Joseph S, Greenwald, Maria White, Holt, Peter A, Johnston, Cyrus Conrad, Fang, Chien, Kiel, Douglas P, Klashman, David J, Lewiecki, E. Michael, Lowenstein, Mitchell B, McClung, Michael Roy, Nattrass, Susan M, Odio, Alberto, Levengood, Julie, Romaguera, Josefina, Saag, Kenneth G, Sebai, Mohamed Bassam, Snyder, Brian, Kutner, Mark Eliot, Streja, Dan, Schwartz, Elliott P, Christiansen, Mark G, McClung, Michael R, O'Donoghue, Michelle L, Papapoulos, Socrates E, Bone, Henry, Langdahl, Bente, Reid, Ian R, Cavallari, Ilaria, Bonaca, Marc P, Wiviott, Stephen D, de Villiers, Tobias, Ling, Xu, Nakamura, Toshitaka, Rodriguez-Portales, Jose Adolfo, Zanchetta, José, Zerbini, Cristiano A F, Park, Jeong-Gun, Im, KyungAh, Cange, Abby, Grip, Laura T, Heyden, Norman, DaSilva, Carolyn, Cohn, Dosinda, Massaad, Rachid, Scott, Boyd B, Verbruggen, Nadia, Gurner, Deborah, Miller, Deborah L, Blair, Micki L, Polis, Adam B, Stoch, S Aubrey, Santora, Arthur, Lombardi, Antonio, Leung, Albert T, Kaufman, Keith D, and Sabatine, Marc S
- Published
- 2019
- Full Text
- View/download PDF
20. Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis – A comparison in a real-world national cohort
- Author
-
Codreanu, Cătălin, Popescu, Claudiu C., Mogoșan, Corina, Enache, Luminița, Daia, Sânziana, Ionescu, Ruxandra, and Opriș-Belinski, Daniela
- Published
- 2019
- Full Text
- View/download PDF
21. Reference interval and upper decission limit for serum uric acid – an evidence-based approach on Romanian population using an a posteriori method
- Author
-
Codreanu Catalin, Popoviciu Horatiu, Rezus Elena, Mogosan Corina Delia, Gardikiotis Ioannis, and Popescu Claudiu Costinel
- Subjects
hyperuricemia ,serum uric acid ,upper limit of normal ,reference intervals ,Medicine - Abstract
Introduction. There is accumulating evidence that high normal serum uric acid (SUA) levels of 6-7 mg/dL are associated with cardiovascular morbidity and metabolic syndrome (MetS), hence the need to redefine its upper limit of normal (ULN). We aimed to derive ULN based on statistics and evidence in a representative sample of the population and to observe its relation to MetS components.
- Published
- 2019
- Full Text
- View/download PDF
22. Evaluation of Microlenses, Color Filters, and Polarizing Filters in CIS for Space Applications
- Author
-
Durnez, Clémentine, primary, Virmontois, Cédric, additional, Panuel, Pierre, additional, Antonsanti, Aubin, additional, Goiffon, Vincent, additional, Estribeau, Magali, additional, Saint-Pé, Olivier, additional, Lalucaa, Valérian, additional, Berdin, Erick, additional, Larnaudie, Franck, additional, Belloir, Jean-Marc, additional, Codreanu, Catalin, additional, and Chavanne, Ludovic, additional
- Published
- 2023
- Full Text
- View/download PDF
23. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries
- Author
-
Linde, Louise, primary, Ørnbjerg, Lykke M, additional, Georgiadis, Stylianos, additional, H. Rasmussen, Simon, additional, Lindström, Ulf, additional, Askling, Johan, additional, Michelsen, Brigitte, additional, Di Giuseppe, Daniela, additional, Wallman, Johan K, additional, Gudbjornsson, Bjorn, additional, Love, Thorvardur Jon, additional, Nordström, Dan C, additional, Yli-Kerttula, Timo, additional, Nekvindová, Lucie, additional, Vencovský, Jiří, additional, Iannone, Florenzo, additional, Cauli, Alberto, additional, Loft, Anne Gitte, additional, Glintborg, Bente, additional, Laas, Karin, additional, Rotar, Ziga, additional, Tomšič, Matija, additional, Macfarlane, Gary J, additional, Möller, Burkhard, additional, van de Sande, Marleen, additional, Codreanu, Catalin, additional, Nissen, Michael J, additional, Birlik, Merih, additional, Erten, Sukran, additional, Santos, Maria J, additional, Vieira-Sousa, Elsa, additional, Hetland, Merete L, additional, and Østergaard, Mikkel, additional
- Published
- 2023
- Full Text
- View/download PDF
24. OA18 Smoking and high BMI are associated with reductions in TNF inhibitor response in psoriatic arthritis: results from 12 European countries
- Author
-
Jones, Gareth T, primary, Rotariu, Ovidiu, additional, Michelsen, Brigitte, additional, Glintborg, Bente, additional, Gudbjornsson, Bjorn, additional, Love, Thorvardur J, additional, Nordström, Dan, additional, Sokka, Tuulikki, additional, Vencovský, Jiří, additional, Horák, Pavel, additional, Rotar, Ziga, additional, Tomšič, Matija, additional, van der Sande, Marleen, additional, Nissen, Michael J, additional, Möller, Burkhard, additional, Codreanu, Catalin, additional, Wallman, Johan K, additional, Fagerli, Karen M, additional, Rasmussen, Simon H, additional, Ørnbjerg, Lykke M, additional, Santos, Maria J, additional, Carvalho, Pedro, additional, Hetland, Merete L, additional, Østergaard, Mikkel, additional, and Macfarlane, Gary J, additional
- Published
- 2023
- Full Text
- View/download PDF
25. Commonalities and differences in set-up and data collection across European spondyloarthritis registries - results from the EuroSpA collaboration
- Author
-
Linde, Louise; https://orcid.org/0000-0003-0863-1352, Ørnbjerg, Lykke M, Rasmussen, Simon H, Love, Thorvardur Jon, Loft, Anne Gitte, Závada, Jakub, Vencovský, Jiří, Laas, Karin, Nordstrom, Dan, Sokka-Isler, Tuulikki, Gudbjornsson, Bjorn, Gröndal, Gerdur, Iannone, Florenzo, Ramonda, Roberta, Hellamand, Pasoon, Kristianslund, Eirik K, Kvien, Tore K, Rodrigues, Ana M, Santos, Maria J, Codreanu, Catalin, Rotar, Ziga, Tomšič, Matija, Castrejon, Isabel, Díaz-Gonzáles, Federico, Di Giuseppe, Daniela, Ljung, Lotta, Nissen, Michael J, Ciurea, Adrian; https://orcid.org/0000-0002-7870-7132, Macfarlane, Gary J, Heddle, Maureen, et al, Linde, Louise; https://orcid.org/0000-0003-0863-1352, Ørnbjerg, Lykke M, Rasmussen, Simon H, Love, Thorvardur Jon, Loft, Anne Gitte, Závada, Jakub, Vencovský, Jiří, Laas, Karin, Nordstrom, Dan, Sokka-Isler, Tuulikki, Gudbjornsson, Bjorn, Gröndal, Gerdur, Iannone, Florenzo, Ramonda, Roberta, Hellamand, Pasoon, Kristianslund, Eirik K, Kvien, Tore K, Rodrigues, Ana M, Santos, Maria J, Codreanu, Catalin, Rotar, Ziga, Tomšič, Matija, Castrejon, Isabel, Díaz-Gonzáles, Federico, Di Giuseppe, Daniela, Ljung, Lotta, Nissen, Michael J, Ciurea, Adrian; https://orcid.org/0000-0002-7870-7132, Macfarlane, Gary J, Heddle, Maureen, and et al
- Abstract
BACKGROUND: In European axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) clinical registries, we aimed to investigate commonalities and differences in (1) set-up, clinical data collection; (2) data availability and completeness; and (3) wording, recall period, and scale used for selected patient-reported outcome measures (PROMs). METHODS: Data was obtained as part of the EuroSpA Research Collaboration Network and consisted of (1) an online survey and follow-up interview, (2) upload of real-world data, and (3) selected PROMs included in the online survey. RESULTS: Fifteen registries participated, contributing 33,948 patients (axSpA: 21,330 (63%), PsA: 12,618 (37%)). The reported coverage of eligible patients ranged from 0.5 to 100%. Information on age, sex, biological/targeted synthetic disease-modifying anti-rheumatic drug treatment, disease duration, and C-reactive protein was available in all registries with data completeness between 85% and 100%. All PROMs (Bath Ankylosing Spondylitis Disease Activity and Functional Indices, Health Assessment Questionnaire, and patient global, pain and fatigue assessments) were more complete after 2015 (68-86%) compared to prior (50-79%). Patient global, pain and fatigue assessments showed heterogeneity between registries in terms of wording, recall periods, and scale. CONCLUSION: Important heterogeneity in registry design and data collection across fifteen European axSpA and PsA registries was observed. Several core measures were widely available, and an increase in data completeness of PROMs in recent years was identified. This study might serve as a basis for examining how differences in data collection across registries may impact the results of collaborative research in the future.
- Published
- 2023
26. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
- Author
-
Michelsen, Brigitte; https://orcid.org/0000-0003-0103-2840, Østergaard, Mikkel, Nissen, Michael John, Ciurea, Adrian; https://orcid.org/0000-0002-7870-7132, Möller, Burkhard; https://orcid.org/0000-0001-8769-6167, Ørnbjerg, Lykke Midtbøll; https://orcid.org/0000-0002-7832-6831, Závada, Jakub, Glintborg, Bente; https://orcid.org/0000-0002-8931-8482, MacDonald, Alan, Laas, Karin, Nordström, Dan, Gudbjornsson, Bjorn, Iannone, Florenzo; https://orcid.org/0000-0003-0474-5344, Hellmand, Pasoon, Kvien, Tore Kristian, Rodrigues, Ana Maria, Codreanu, Catalin, Rotar, Žiga, Castrejón Fernández, Isabel, Wallman, Johan Karlsson, Vencovský, Jiří; https://orcid.org/0000-0002-0851-0713, Loft, Anne Gitte; https://orcid.org/0000-0001-6374-841X, Heddle, Maureen, Vorobjov, Sigrid, Hokkanen, Anna-Mari, Gröndal, Gerdur, Sebastiani, Marco, van de Sande, Marleen, Kristianslund, Eirik Klami, Santos, Maria José; https://orcid.org/0000-0002-7946-1365, et al, Michelsen, Brigitte; https://orcid.org/0000-0003-0103-2840, Østergaard, Mikkel, Nissen, Michael John, Ciurea, Adrian; https://orcid.org/0000-0002-7870-7132, Möller, Burkhard; https://orcid.org/0000-0001-8769-6167, Ørnbjerg, Lykke Midtbøll; https://orcid.org/0000-0002-7832-6831, Závada, Jakub, Glintborg, Bente; https://orcid.org/0000-0002-8931-8482, MacDonald, Alan, Laas, Karin, Nordström, Dan, Gudbjornsson, Bjorn, Iannone, Florenzo; https://orcid.org/0000-0003-0474-5344, Hellmand, Pasoon, Kvien, Tore Kristian, Rodrigues, Ana Maria, Codreanu, Catalin, Rotar, Žiga, Castrejón Fernández, Isabel, Wallman, Johan Karlsson, Vencovský, Jiří; https://orcid.org/0000-0002-0851-0713, Loft, Anne Gitte; https://orcid.org/0000-0001-6374-841X, Heddle, Maureen, Vorobjov, Sigrid, Hokkanen, Anna-Mari, Gröndal, Gerdur, Sebastiani, Marco, van de Sande, Marleen, Kristianslund, Eirik Klami, Santos, Maria José; https://orcid.org/0000-0002-7946-1365, and et al
- Abstract
This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021-April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied considerably. In several countries, for PsA patients with significant skin involvement, interleukin-17 inhibitors were not given preference. The positioning of Janus Kinase inhibitors differed and Phosphodiesterase-4 inhibitors were not in use/reimbursed in most countries. This study may motivate European countries to update their national treatment recommendations, to align them better with the latest international recommendations.
- Published
- 2023
27. Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis:Results from the EuroSpA Research Collaboration Network
- Author
-
Hellamand, Pasoon, Van De Sande, Marleen, Ørnbjerg, Lykke Midtbøll, Klausch, Thomas, Nurmohamed, Michael T., Van Vollenhoven, Ronald F., Nordström, Dan, Hokkanen, Anna Mari, Santos, Maria Jose, Vieira-Sousa, Elsa, Loft, Anne G., Glintborg, Bente, Hetland, Merete Lund, Lindström, Ulf, Wallman, Johan K., Michelsen, Brigitte, Klami Kristianslund, Eirik, Ciurea, Adrian, Nissen, Michael S., Codreanu, Catalin, Mogosan, Corina, Macfarlane, Gary J., Rotariu, Ovidiu, Rotar, Ziga, Tomšič, Matija, Castrejon, Isabel, Otero-Varela, Lucia, Gudbjornsson, Bjorn, Geirsson, Arni Jon, Vencovský, Ji, Pavelka, Karel, Gulle, Semih, Zengin, Berrin, Iannone, Florenzo, Foti, Rosario, Ostergaard, Mikkel, Van Der Horst-Bruinsma, Irene, Hellamand, Pasoon, Van De Sande, Marleen, Ørnbjerg, Lykke Midtbøll, Klausch, Thomas, Nurmohamed, Michael T., Van Vollenhoven, Ronald F., Nordström, Dan, Hokkanen, Anna Mari, Santos, Maria Jose, Vieira-Sousa, Elsa, Loft, Anne G., Glintborg, Bente, Hetland, Merete Lund, Lindström, Ulf, Wallman, Johan K., Michelsen, Brigitte, Klami Kristianslund, Eirik, Ciurea, Adrian, Nissen, Michael S., Codreanu, Catalin, Mogosan, Corina, Macfarlane, Gary J., Rotariu, Ovidiu, Rotar, Ziga, Tomšič, Matija, Castrejon, Isabel, Otero-Varela, Lucia, Gudbjornsson, Bjorn, Geirsson, Arni Jon, Vencovský, Ji, Pavelka, Karel, Gulle, Semih, Zengin, Berrin, Iannone, Florenzo, Foti, Rosario, Ostergaard, Mikkel, and Van Der Horst-Bruinsma, Irene
- Abstract
Objective Evidence indicates reduced treatment effectiveness of TNFi in women with axial spondyloarthritis (axSpA) compared with men. We aimed to investigate sex differences in treatment response and retention rates over 24 months of follow-up in axSpA patients initiating their first TNFi. Methods Data from axSpA patients initiating a TNFi in 1 of 15 registries within EuroSpA collaboration were pooled. We investigated the association of sex with treatment response using logistic regression. The primary outcome was clinically important improvement (CII) at 6 months according to Ankylosing Spondylitis Disease Activity Score with C-reactive protein (CRP) (≥1.1 decrease). We adjusted for age, country and TNFi start year. A secondary outcome was retention rates over 24 months of follow-up assessed by Kaplan-Meier estimator. Results In total, 6451 axSpA patients with data on CII were assessed for treatment response; 2538 (39%) were women and 3913 (61%) were men. Women presented at baseline with lower CRP levels but had higher scores on patient-reported outcome measures. At 6 months, 53% of the women and 66% of the men had CII. Women had a lower relative risk of CII compared with men (0.81; 95% CI 0.77 to 0.84). This sex difference was similar in adjusted analysis (0.85; 95% CI 0.82 to 0.88). Retention rates were evaluated in 27 702 patients. The TNFi 6/12/24 months retention rates were significantly lower among women (79%/66%/53%) than men (88%/79%/69%). Conclusion Treatment response and retention rates are lower among women with axSpA initiating their first TNFi. Sex differences in treatment effectiveness were present regardless of the outcome measure used for treatment response, and differences in retention rates transpired early and increased as time progressed., Objective Evidence indicates reduced treatment effectiveness of TNFi in women with axial spondyloarthritis (axSpA) compared with men. We aimed to investigate sex differences in treatment response and retention rates over 24 months of follow-up in axSpA patients initiating their first TNFi. Methods Data from axSpA patients initiating a TNFi in 1 of 15 registries within EuroSpA collaboration were pooled. We investigated the association of sex with treatment response using logistic regression. The primary outcome was clinically important improvement (CII) at 6 months according to Ankylosing Spondylitis Disease Activity Score with C-reactive protein (CRP) (≥1.1 decrease). We adjusted for age, country and TNFi start year. A secondary outcome was retention rates over 24 months of follow-up assessed by Kaplan-Meier estimator. Results In total, 6451 axSpA patients with data on CII were assessed for treatment response; 2538 (39%) were women and 3913 (61%) were men. Women presented at baseline with lower CRP levels but had higher scores on patient-reported outcome measures. At 6 months, 53% of the women and 66% of the men had CII. Women had a lower relative risk of CII compared with men (0.81; 95% CI 0.77 to 0.84). This sex difference was similar in adjusted analysis (0.85; 95% CI 0.82 to 0.88). Retention rates were evaluated in 27 702 patients. The TNFi 6/12/24 months retention rates were significantly lower among women (79%/66%/53%) than men (88%/79%/69%). Conclusion Treatment response and retention rates are lower among women with axSpA initiating their first TNFi. Sex differences in treatment effectiveness were present regardless of the outcome measure used for treatment response, and differences in retention rates transpired early and increased as time progressed.
- Published
- 2023
28. One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
- Author
-
Ørnbjerg, Lykke Midtbøll, Rugbjerg, Kathrine, Georgiadis, Stylianos, Rasmussen, Simon Horskjær, Lindström, Ulf, Pavelka, Karel, Yilmaz, Neslihan, Favalli, Ennio Giulio, Nissen, Michael J, Michelsen, Brigitte, Vieira-Sousa, Elsa, Jones, Gareth T, Ionescu, Ruxandra, Relas, Heikki, Sanchez-Piedra, Carlos, Tomšič, Matija, Geirsson, Arni Jon, van der Horst-Bruinsma, Irene, Askling, Johan, Loft, Anne Gitte, Nekvindova, Lucie, Direskeneli, Haner, Iannone, Florenzo, Ciurea, Adrian, Fagerli, Karen Minde, Santos, Maria José, Macfarlane, Gary J, Codreanu, Catalin, Eklund, Kari, Pombo-Suarez, Manuel, Rotar, Ziga, Gudbjornsson, Bjorn, Rusman, Tamara, Østergaard, Mikkel, Hetland, Merete Lund, Ørnbjerg, Lykke Midtbøll, Rugbjerg, Kathrine, Georgiadis, Stylianos, Rasmussen, Simon Horskjær, Lindström, Ulf, Pavelka, Karel, Yilmaz, Neslihan, Favalli, Ennio Giulio, Nissen, Michael J, Michelsen, Brigitte, Vieira-Sousa, Elsa, Jones, Gareth T, Ionescu, Ruxandra, Relas, Heikki, Sanchez-Piedra, Carlos, Tomšič, Matija, Geirsson, Arni Jon, van der Horst-Bruinsma, Irene, Askling, Johan, Loft, Anne Gitte, Nekvindova, Lucie, Direskeneli, Haner, Iannone, Florenzo, Ciurea, Adrian, Fagerli, Karen Minde, Santos, Maria José, Macfarlane, Gary J, Codreanu, Catalin, Eklund, Kari, Pombo-Suarez, Manuel, Rotar, Ziga, Gudbjornsson, Bjorn, Rusman, Tamara, Østergaard, Mikkel, and Hetland, Merete Lund
- Abstract
Objective To investigate the distribution of patient-reported outcomes (PROs) in patients with axial spondyloarthritis (axSpA) initiating a tumor necrosis factor inhibitor (TNFi), to assess the proportion reaching PRO "remission" across registries and treatment series, and to compare patients registered to fulfill the modified New York (mNY) criteria for ankylosing spondylitis (AS) vs patients with nonradiographic axSpA (nr-axSpA). Methods Fifteen European registries contributed PRO scores for pain, fatigue, patient global assessment (PtGA), Bath Ankylosing Spondylitis (AS) Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), and Health Assessment Questionnaire (HAQ) from 19,498 patients with axSpA. Changes in PROs and PRO remission rates (definitions: ≤ 20 mm for pain, fatigue, PtGA, BASDAI, and BASFI; ≤ 0.5 for HAQ) were calculated at 6, 12, and 24 months of treatment. Results Heterogeneity in baseline characteristics and outcomes between registries were observed. In pooled data, 6 months after the start of a first TNFi, pain score was reduced by approximately 60% (median at baseline/ 6/12/24 months: 65/25/20/20 mm) in patients on treatment. Similar patterns were observed for fatigue (68/32/30/25 mm), PtGA (66/29/21/20 mm), BASDAI (58/26/21/19 mm), BASFI (46/20/16/16 mm), and HAQ (0.8/0.4/0.2/0.2). Patients with AS (n = 3281) had a slightly better response than patients with nr-axSpA (n = 993). The Lund Efficacy Index (LUNDEX)-adjusted remission rates at 6 months for pain/fatigue/PtGA/BASDAI/BASFI/HAQ were 39%/30%/38%/34%/35%/48% for the AS cohort and 30%/21%/26%/24%/33%/47% for the nr-axSpA cohort. Better PRO responses were seen with a first TNFi compared to a second and third TNFi. Conclusion Patients with axSpA starting a TNFi achieved high PRO remission rates, most pronounced in those fulfilling the mNY criteria and for the first TNFi., OBJECTIVE: To investigate the distribution of patient-reported outcomes (PROs) in patients with axial spondyloarthritis (axSpA) initiating a tumor necrosis factor inhibitor (TNFi), to assess the proportion reaching PRO "remission" across registries and treatment series, and to compare patients registered to fulfill the modified New York (mNY) criteria for ankylosing spondylitis (AS) vs patients with nonradiographic axSpA (nr-axSpA).METHODS: Fifteen European registries contributed PRO scores for pain, fatigue, patient global assessment (PtGA), Bath Ankylosing Spondylitis (AS) Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), and Health Assessment Questionnaire (HAQ) from 19,498 patients with axSpA. Changes in PROs and PRO remission rates (definitions: ≤ 20 mm for pain, fatigue, PtGA, BASDAI, and BASFI; ≤ 0.5 for HAQ) were calculated at 6, 12, and 24 months of treatment.RESULTS: Heterogeneity in baseline characteristics and outcomes between registries were observed. In pooled data, 6 months after the start of a first TNFi, pain score was reduced by approximately 60% (median at baseline/ 6/12/24 months: 65/25/20/20 mm) in patients on treatment. Similar patterns were observed for fatigue (68/32/30/25 mm), PtGA (66/29/21/20 mm), BASDAI (58/26/21/19 mm), BASFI (46/20/16/16 mm), and HAQ (0.8/0.4/0.2/0.2). Patients with AS (n = 3281) had a slightly better response than patients with nr-axSpA (n = 993). The Lund Efficacy Index (LUNDEX)-adjusted remission rates at 6 months for pain/fatigue/PtGA/BASDAI/BASFI/HAQ were 39%/30%/38%/34%/35%/48% for the AS cohort and 30%/21%/26%/24%/33%/47% for the nr-axSpA cohort. Better PRO responses were seen with a first TNFi compared to a second and third TNFi.CONCLUSION: Patients with axSpA starting a TNFi achieved high PRO remission rates, most pronounced in those fulfilling the mNY criteria and for the first TNFi.
- Published
- 2023
29. Corrigendum to ‘Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration’ [Seminars in Arthritis and Rheumatism 56 (2022) 1-13/152081]
- Author
-
Ørnbjerg, Lykke M., primary, Linde, Louise, additional, Georgiadis, Stylianos, additional, Rasmussen, Simon H., additional, Lindström, Ulf, additional, Askling, Johan, additional, Michelsen, Brigitte, additional, Giuseppe, Daniela Di, additional, Wallman, Johan K., additional, Pavelka, Karel, additional, Závada, Jakub, additional, Nissen, Michael J., additional, Jones, Gareth T., additional, Relas, Heikki, additional, Pirilä, Laura, additional, Tomšič, Matija, additional, Rotar, Ziga, additional, Geirsson, Arni Jon, additional, Gudbjornsson, Bjorn, additional, Kristianslund, Eirik K., additional, van der Horst-Bruinsma, Irene, additional, Loft, Anne Gitte, additional, Laas, Karin, additional, Iannone, Florenzo, additional, Corrado, Addolorata, additional, Ciurea, Adrian, additional, Santos, Maria J., additional, Santos, Helena, additional, Codreanu, Catalin, additional, Akkoc, Nurullah, additional, Gunduz, Ozgul S., additional, Glintborg, Bente, additional, Østergaard, Mikkel, additional, and Hetland, Merete Lund, additional
- Published
- 2023
- Full Text
- View/download PDF
30. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
- Author
-
Smolen, Josef S., Landewé, Robert B. M., Bergstra, Sytske Anne, Kerschbaumer, Andreas, Sepriano, Alexandre, Aletaha, Daniel, Caporali, Roberto, Edwards, Christopher John, Hyrich, Kimme L., Pope, Janet E., de Souza, Savia, Stamm, Tanja A., Takeuchi, Tsutomu, Verschueren, Patrick, Winthrop, Kevin L., Balsa, Alejandro, Bathon, Joan M., Buch, Maya H., Burmester, Gerd R., Buttgereit, Frank, Cardiel, Mario Humberto, Chatzidionysiou, Katerina, Codreanu, Catalin, Cutolo, Maurizio, den Broeder, Alfons A., el Aoufy, Khadija, Finckh, Axel, Fonseca, João Eurico, Gottenberg, Jacques-Eric, Haavardsholm, Espen A., Iagnocco, Annamaria, Lauper, Kim, Li, Zhanguo, McInnes, Iain B., Mysler, Eduardo F., Nash, Peter, Poor, Gyula, Ristic, Gorica G., Rivellese, Felice, Rubbert-Roth, Andrea, Schulze-Koops, Hendrik, Stoilov, Nikolay, Strangfeld, Anja, van der Helm-van Mil, Annette, van Duuren, Elsa, Vliet Vlieland, Theodora P. M., Westhovens, René, van der Heijde, D. sirée, Clinical Immunology and Rheumatology, and AII - Inflammatory diseases
- Subjects
Arthritis, Rheumatoid ,Biological Therapy ,All institutes and research themes of the Radboud University Medical Center ,Rheumatology ,Arthritis ,Rheumatoid ,Antirheumatic Agents ,Immunology ,Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5] ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
ObjectivesTo provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field.MethodsAn international task force was formed and solicited three systematic literature research activities on safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs). The new evidence was discussed in light of the last update from 2019. A predefined voting process was applied to each overarching principle and recommendation. Levels of evidence and strengths of recommendation were assigned to and participants finally voted on the level of agreement with each item.ResultsThe task force agreed on 5 overarching principles and 11 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); GCs; biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab including biosimilars), abatacept, rituximab, tocilizumab, sarilumab and targeted synthetic (ts) DMARDs, namely the Janus kinase inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib. Guidance on monotherapy, combination therapy, treatment strategies (treat-to-target) and tapering in sustained clinical remission is provided. Safety aspects, including risk of major cardiovascular events (MACEs) and malignancies, costs and sequencing of b/tsDMARDs were all considered. Initially, MTX plus GCs is recommended and on insufficient response to this therapy within 3–6 months, treatment should be based on stratification according to risk factors; With poor prognostic factors (presence of autoantibodies, high disease activity, early erosions or failure of two csDMARDs), any bDMARD should be added to the csDMARD; after careful consideration of risks of MACEs, malignancies and/or thromboembolic events tsDMARDs may also be considered in this phase. If the first bDMARD (or tsDMARD) fails, any other bDMARD (from another or the same class) or tsDMARD (considering risks) is recommended. With sustained remission, DMARDs may be tapered but should not be stopped. Levels of evidence and levels of agreement were high for most recommendations.ConclusionsThese updated EULAR recommendations provide consensus on RA management including safety, effectiveness and cost.
- Published
- 2023
31. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor: results from 13 European registries
- Author
-
Linde, Louise, Ørnbjerg, Lykke M, Georgiadis, Stylianos, Rasmussen, Simon H, Lindström, Ulf, Askling, Johan, Michelsen, Brigitte, Di Giuseppe, Daniela, Wallman, Johan K, Gudbjornsson, Bjorn, Love, Thorvardur Jon, Nordström, Dan C, Yli-Kerttula, Timo, Nekvindová, Lucie, Vencovský, Jiří, Iannone, Florenzo, Cauli, Alberto, Loft, Anne Gitte, Glintborg, Bente, Laas, Karin, Rotar, Ziga, Tomšič, Matija, Macfarlane, Gary J, Möller, Burkhard, van de Sande, Marleen, Codreanu, Catalin, Nissen, Michael J, Birlik, Merih, Erten, Sukran, Santos, Maria J, Vieira-Sousa, Elsa, Hetland, Merete L, and Østergaard, Mikkel
- Subjects
610 Medicine & health - Abstract
OBJECTIVES In bio-naïve patients with Psoriatic arthritis (PsA) initiating a Tumour Necrosis Factor inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries. METHODS Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes, were defined as common predictors. RESULTS In the pooled cohort (n = 13 369), six-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n = 6,954, n = 5,275 and n = 13 369, respectively). Baseline predictors of remission, moderate response and 12-month drug retention were identified, five common across all three outcomes. Odds ratios (95% confidence interval) for DAPSA28 remission were: age, per year: 0.97 (0.96-0.98); disease duration, years (< 2 years as reference): 2-3 years: 1.20 (0.89-1.60), 4-9 years: 1.42 (1.09-1.84), ≥10 years: 1.66 (1.26-2.20); men vs women: 1.85 (1.54-2.23); CRP >10 vs ≤ 10 mg/l: 1.52 (1.22-1.89) and one mm increase in patient fatigue score: 0.99 (0.98-0.99). CONCLUSION Baseline predictors of remission, response and adherence to TNFi were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalisable from the country- to disease-level.
- Published
- 2023
- Full Text
- View/download PDF
32. One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
- Author
-
Ørnbjerg, Lykke Midtbøll, primary, Rugbjerg, Kathrine, additional, Georgiadis, Stylianos, additional, Rasmussen, Simon Horskjær, additional, Lindström, Ulf, additional, Pavelka, Karel, additional, Yilmaz, Neslihan, additional, Favalli, Ennio Giulio, additional, Nissen, Michael J., additional, Michelsen, Brigitte, additional, Vieira-Sousa, Elsa, additional, Jones, Gareth T., additional, Ionescu, Ruxandra, additional, Relas, Heikki, additional, Sanchez-Piedra, Carlos, additional, Tomšič, Matija, additional, Geirsson, Arni Jon, additional, van der Horst-Bruinsma, Irene, additional, Askling, Johan, additional, Loft, Anne Gitte, additional, Nekvindova, Lucie, additional, Direskeneli, Haner, additional, Iannone, Florenzo, additional, Ciurea, Adrian, additional, Fagerli, Karen Minde, additional, Santos, Maria José, additional, Macfarlane, Gary J., additional, Codreanu, Catalin, additional, Eklund, Kari, additional, Pombo-Suarez, Manuel, additional, Rotar, Ziga, additional, Gudbjornsson, Bjorn, additional, Rusman, Tamara, additional, Østergaard, Mikkel, additional, and Hetland, Merete Lund, additional
- Published
- 2022
- Full Text
- View/download PDF
33. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
- Author
-
Smolen, Josef S, primary, Landewé, Robert B M, additional, Bergstra, Sytske Anne, additional, Kerschbaumer, Andreas, additional, Sepriano, Alexandre, additional, Aletaha, Daniel, additional, Caporali, Roberto, additional, Edwards, Christopher John, additional, Hyrich, Kimme L, additional, Pope, Janet E, additional, de Souza, Savia, additional, Stamm, Tanja A, additional, Takeuchi, Tsutomu, additional, Verschueren, Patrick, additional, Winthrop, Kevin L, additional, Balsa, Alejandro, additional, Bathon, Joan M, additional, Buch, Maya H, additional, Burmester, Gerd R, additional, Buttgereit, Frank, additional, Cardiel, Mario Humberto, additional, Chatzidionysiou, Katerina, additional, Codreanu, Catalin, additional, Cutolo, Maurizio, additional, den Broeder, Alfons A, additional, El Aoufy, Khadija, additional, Finckh, Axel, additional, Fonseca, João Eurico, additional, Gottenberg, Jacques-Eric, additional, Haavardsholm, Espen A, additional, Iagnocco, Annamaria, additional, Lauper, Kim, additional, Li, Zhanguo, additional, McInnes, Iain B, additional, Mysler, Eduardo F, additional, Nash, Peter, additional, Poor, Gyula, additional, Ristic, Gorica G, additional, Rivellese, Felice, additional, Rubbert-Roth, Andrea, additional, Schulze-Koops, Hendrik, additional, Stoilov, Nikolay, additional, Strangfeld, Anja, additional, van der Helm-van Mil, Annette, additional, van Duuren, Elsa, additional, Vliet Vlieland, Theodora P M, additional, Westhovens, René, additional, and van der Heijde, Désirée, additional
- Published
- 2022
- Full Text
- View/download PDF
34. One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
- Author
-
Ørnbjerg, Lykke Midtbøll, Rugbjerg, Kathrine, Georgiadis, Stylianos, Rasmussen, Simon Horskjær, Lindström, Ulf, Pavelka, Karel, Yilmaz, Neslihan, Favalli, Ennio Giulio, Nissen, Michael J, Michelsen, Brigitte, Vieira-Sousa, Elsa, Jones, Gareth T, Ionescu, Ruxandra, Relas, Heikki, Sanchez-Piedra, Carlos, Tomšič, Matija, Geirsson, Arni Jon, van der Horst-Bruinsma, Irene, Askling, Johan, Loft, Anne Gitte, Nekvindova, Lucie, Direskeneli, Haner, Iannone, Florenzo, Ciurea, Adrian, Fagerli, Karen Minde, Santos, Maria José, Macfarlane, Gary J, Codreanu, Catalin, Eklund, Kari, Pombo-Suarez, Manuel, et al, and University of Zurich
- Subjects
10051 Rheumatology Clinic and Institute of Physical Medicine ,610 Medicine & health - Published
- 2022
35. 2022 update
- Author
-
Smolen, Josef S., Landewé, Robert B.M., Bergstra, Sytske Anne, Kerschbaumer, Andreas, Sepriano, Alexandre, Aletaha, Daniel, Caporali, Roberto, Edwards, Christopher John, Hyrich, Kimme L., Pope, Janet E., De Souza, Savia, Stamm, Tanja A., Takeuchi, Tsutomu, Verschueren, Patrick, Winthrop, Kevin L., Balsa, Alejandro, Bathon, Joan M., Buch, Maya H., Burmester, Gerd R., Buttgereit, Frank, Cardiel, Mario Humberto, Chatzidionysiou, Katerina, Codreanu, Catalin, Cutolo, Maurizio, Den Broeder, Alfons A., El Aoufy, Khadija, Finckh, Axel, Fonseca, João Eurico, Gottenberg, Jacques Eric, Haavardsholm, Espen A., Iagnocco, Annamaria, Lauper, Kim, Li, Zhanguo, McInnes, Iain B., Mysler, Eduardo F., Nash, Peter, Poor, Gyula, Ristic, Gorica G., Rivellese, Felice, Rubbert-Roth, Andrea, Schulze-Koops, Hendrik, Stoilov, Nikolay, Strangfeld, Anja, Van Der Helm-Van Mil, Annette, Van Duuren, Elsa, Vliet Vlieland, Theodora P.M., Westhovens, René, Van Der Heijde, Désirée, NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), and Comprehensive Health Research Centre (CHRC) - pólo NMS
- Subjects
Arthritis, Rheumatoid ,Biological Therapy ,Rheumatology ,Biochemistry, Genetics and Molecular Biology(all) ,Antirheumatic Agents ,Immunology ,Immunology and Allergy - Abstract
Funding Information: This study was funded by European League Against Rheumatism. Publisher Copyright: © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. Objectives: To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field. Methods: An international task force was formed and solicited three systematic literature research activities on safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs). The new evidence was discussed in light of the last update from 2019. A predefined voting process was applied to each overarching principle and recommendation. Levels of evidence and strengths of recommendation were assigned to and participants finally voted on the level of agreement with each item. Results: The task force agreed on 5 overarching principles and 11 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); GCs; biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab including biosimilars), abatacept, rituximab, tocilizumab, sarilumab and targeted synthetic (ts) DMARDs, namely the Janus kinase inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib. Guidance on monotherapy, combination therapy, treatment strategies (treat-to-target) and tapering in sustained clinical remission is provided. Safety aspects, including risk of major cardiovascular events (MACEs) and malignancies, costs and sequencing of b/tsDMARDs were all considered. Initially, MTX plus GCs is recommended and on insufficient response to this therapy within 3-6 months, treatment should be based on stratification according to risk factors; With poor prognostic factors (presence of autoantibodies, high disease activity, early erosions or failure of two csDMARDs), any bDMARD should be added to the csDMARD; after careful consideration of risks of MACEs, malignancies and/or thromboembolic events tsDMARDs may also be considered in this phase. If the first bDMARD (or tsDMARD) fails, any other bDMARD (from another or the same class) or tsDMARD (considering risks) is recommended. With sustained remission, DMARDs may be tapered but should not be stopped. Levels of evidence and levels of agreement were high for most recommendations. Conclusions: These updated EULAR recommendations provide consensus on RA management including safety, effectiveness and cost. publishersversion published
- Published
- 2022
36. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration
- Author
-
Ørnbjerg, Lykke Midtbøll, Linde, Louise, Georgiadis, Stylianos, Rasmussen, Simon H, Lindström, Ulf, Askling, Johan, Michelsen, Brigitte, Giuseppe, Daniela Di, Wallman, Johan K, Pavelka, Karel, Závada, Jakub, Nissen, Michael J, Jones, Gareth T, Relas, Heikki, Pirilä, Laura, Tomšič, Matija, Rotar, Žiga, Geirsson, Árni Jón, Gudbjornsson, Bjorn, Kristianslund, Eirik K, van Sder Horst-Bruinsma, Irene, Loft, Anne Gitte, Laas, Karin, Iannone, Florenzo, Corrado, Addolorata, Ciurea, Adrian, Santos, Maria J, Santos, Helena, Codreanu, Catalin, Akkoc, Nurullah, et al, and University of Zurich
- Subjects
10051 Rheumatology Clinic and Institute of Physical Medicine ,610 Medicine & health - Published
- 2022
37. After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries
- Author
-
Pombo-Suarez, Manuel, primary, Sanchez-Piedra, Carlos, additional, Gómez-Reino, Juan, additional, Lauper, Kim, additional, Mongin, Denis, additional, Iannone, Florenzo, additional, Pavelka, Karel, additional, Nordström, Dan C, additional, Inanc, Nevsun, additional, Codreanu, Catalin, additional, Hyrich, Kimme L, additional, Choquette, Denis, additional, Strangfeld, Anja, additional, Leeb, Burkhard F, additional, Rotar, Ziga, additional, Rodrigues, Ana, additional, Kristianslund, Eirik Klami, additional, Kvien, Tore K, additional, Elkayam, Ori, additional, Lukina, Galina, additional, Bergstra, Sytske Anne, additional, Finckh, Axel, additional, and Courvoisier, Delphine Sophie, additional
- Published
- 2022
- Full Text
- View/download PDF
38. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update
- Author
-
Aletaha, Daniel, primary, Kerschbaumer, Andreas, additional, Kastrati, Kastriot, additional, Dejaco, Christian, additional, Dougados, Maxime, additional, McInnes, Iain B, additional, Sattar, Naveed, additional, Stamm, Tanja A, additional, Takeuchi, Tsutomu, additional, Trauner, Michael, additional, van der Heijde, Désirée, additional, Voshaar, Marieke, additional, Winthrop, Kevin L, additional, Ravelli, Angelo, additional, Betteridge, Neil, additional, Burmester, Gerd-Rüdiger R, additional, Bijlsma, Johannes WJ, additional, Bykerk, Vivian, additional, Caporali, Roberto, additional, Choy, Ernest H, additional, Codreanu, Catalin, additional, Combe, Bernard, additional, Crow, Mary K, additional, de Wit, Maarten, additional, Emery, Paul, additional, Fleischmann, Roy M, additional, Gabay, Cem, additional, Hetland, Merete Lund, additional, Hyrich, Kimme L, additional, Iagnocco, Annamaria, additional, Isaacs, John D, additional, Kremer, Joel M, additional, Mariette, Xavier, additional, Merkel, Peter A, additional, Mysler, Eduardo F, additional, Nash, Peter, additional, Nurmohamed, Michael T, additional, Pavelka, Karel, additional, Poor, Gyula, additional, Rubbert-Roth, Andrea, additional, Schulze-Koops, Hendrik, additional, Strangfeld, Anja, additional, Tanaka, Yoshiya, additional, and Smolen, Josef S, additional
- Published
- 2022
- Full Text
- View/download PDF
39. Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries
- Author
-
Péntek, Márta, Poór, Gyula, Wiland, Piotr, Olejárová, Martina, Brzosko, Marek, Codreanu, Catalin, Brodszky, Nóra, and Gulácsi, László
- Published
- 2014
40. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis
- Author
-
Nissen, Michael, Delcoigne, Bénédicte, Di Giuseppe, Daniela, Jacobsson, Lennart, Hetland, Merete Lund, Ciurea, Adrian, Nekvindova, Lucie, Iannone, Florenzo, Akkoc, Nurullah, Sokka-Isler, Tuulikki, Fagerli, Karen Minde, Santos, Maria Jose, Codreanu, Catalin, Pombo-Suarez, Manuel, Rotar, Ziga, Gudbjornsson, Bjorn, van der Horst-Bruinsma, Irene, Loft, Anne Gitte, Möller, Burkhard, Mann, Herman, Conti, Fabrizio, Yildirim Cetin, Gozde, Relas, Heikki, Michelsen, Brigitte, Avila Ribeiro, Pedro, Ionescu, Ruxandra, Sanchez-Piedra, Carlos, Tomsic, Matija, Geirsson, Árni Jón, Askling, Johan, Glintborg, Bente, Lindström, Ulf, Nissen, Michael, Delcoigne, Bénédicte, Di Giuseppe, Daniela, Jacobsson, Lennart, Hetland, Merete Lund, Ciurea, Adrian, Nekvindova, Lucie, Iannone, Florenzo, Akkoc, Nurullah, Sokka-Isler, Tuulikki, Fagerli, Karen Minde, Santos, Maria Jose, Codreanu, Catalin, Pombo-Suarez, Manuel, Rotar, Ziga, Gudbjornsson, Bjorn, van der Horst-Bruinsma, Irene, Loft, Anne Gitte, Möller, Burkhard, Mann, Herman, Conti, Fabrizio, Yildirim Cetin, Gozde, Relas, Heikki, Michelsen, Brigitte, Avila Ribeiro, Pedro, Ionescu, Ruxandra, Sanchez-Piedra, Carlos, Tomsic, Matija, Geirsson, Árni Jón, Askling, Johan, Glintborg, Bente, and Lindström, Ulf
- Abstract
OBJECTIVES: Many axial spondylarthritis (axSpA) patients receive a conventional synthetic DMARD (csDMARD) in combination with a TNF inhibitor (TNFi). However, the value of this co-therapy remains unclear. The objectives were to describe the characteristics of axSpA patients initiating a first TNFi as monotherapy compared with co-therapy with csDMARD, to compare one-year TNFi retention and remission rates, and to explore the impact of peripheral arthritis. METHODS: Data was collected from 13 European registries. One-year outcomes included TNFi retention and hazard ratios (HR) for discontinuation with 95% CIs. Logistic regression was performed with adjusted odds ratios (OR) of achieving remission (Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP < 1.3 and/or BASDAI < 2) and stratified by treatment. Inter-registry heterogeneity was assessed using random-effect meta-analyses, combined results were presented when heterogeneity was not significant. Peripheral arthritis was defined as ≥1 swollen joint at baseline (=TNFi start). RESULTS: Amongst 24 171 axSpA patients, 32% received csDMARD co-therapy (range across countries: 13.5% to 71.2%). The co-therapy group had more baseline peripheral arthritis and higher CRP than the monotherapy group. One-year TNFi-retention rates (95% CI): 79% (78, 79%) for TNFi monotherapy vs 82% (81, 83%) with co-therapy (P < 0.001). Remission was obtained in 20% on monotherapy and 22% on co-therapy (P < 0.001); adjusted OR of 1.16 (1.07, 1.25). Remission rates at 12 months were similar in patients with/without peripheral arthritis. CONCLUSION: This large European study of axial SpA patients showed similar one-year treatment outcomes for TNFi monotherapy and csDMARD co-therapy, although considerable heterogeneity across countries limited the identification of certain subgroups (e.g. peripheral arthritis) that may benefit from co-therapy.
- Published
- 2022
41. European bio-naïve spondyloarthritis patients initiating TNF inhibitor:time trends in baseline characteristics, treatment retention and response
- Author
-
Christiansen, Sara Nysom, Ørnbjerg, Lykke Midtbøll, Rasmussen, Simon Horskjær, Loft, Anne Gitte, Askling, Johan, Iannone, Florenzo, Zavada, Jakub, Michelsen, Brigitte, Nissen, Michael, Onen, Fatos, Santos, Maria Jose, Pombo-Suarez, Manuel, Relas, Heikki, Macfarlane, Gary J., Tomsic, Matija, Codreanu, Catalin, Gudbjornsson, Bjorn, Van der Horst-Bruinsma, Irene, Di Giuseppe, Daniela, Glintborg, Bente, Gremese, Elisa, Pavelka, Karel, Kristianslund, Eirik Klami, Ciurea, Adrian, Akkoc, Nurullah, Barcelos, Anabela, Sánchez-Piedra, Carlos, Peltomaa, Ritva, Jones, Gareth T., Rotar, Ziga, Ionescu, Ruxandra, Grondal, Gerdur, Van de Sande, Marleen G.H., Laas, Karin, Østergaard, Mikkel, Hetland, Merete L., Christiansen, Sara Nysom, Ørnbjerg, Lykke Midtbøll, Rasmussen, Simon Horskjær, Loft, Anne Gitte, Askling, Johan, Iannone, Florenzo, Zavada, Jakub, Michelsen, Brigitte, Nissen, Michael, Onen, Fatos, Santos, Maria Jose, Pombo-Suarez, Manuel, Relas, Heikki, Macfarlane, Gary J., Tomsic, Matija, Codreanu, Catalin, Gudbjornsson, Bjorn, Van der Horst-Bruinsma, Irene, Di Giuseppe, Daniela, Glintborg, Bente, Gremese, Elisa, Pavelka, Karel, Kristianslund, Eirik Klami, Ciurea, Adrian, Akkoc, Nurullah, Barcelos, Anabela, Sánchez-Piedra, Carlos, Peltomaa, Ritva, Jones, Gareth T., Rotar, Ziga, Ionescu, Ruxandra, Grondal, Gerdur, Van de Sande, Marleen G.H., Laas, Karin, Østergaard, Mikkel, and Hetland, Merete L.
- Abstract
OBJECTIVES: To investigate time trends in baseline characteristics and retention, remission and response rates in bio-naïve axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating TNF inhibitor (TNFi) treatment. METHODS: Prospectively collected data on bio-naïve axSpA and PsA patients from routine care in 15 European countries were pooled. Three cohorts were defined according to year of TNFi initiation: A (1999-2008), B (2009-2014) and C (2015-2018). Retention, remission and response rates were assessed at 6, 12 and 24 months. RESULTS: In total, 27 149 axSpA and 17 446 PsA patients were included. Cohort A patients had longer disease duration compared with B and C. In axSpA, cohort A had the largest proportion of male and HLA-B27 positive patients. In PsA, baseline disease activity was highest in cohort A. Retention rates in axSpA/PsA were highest in cohort A and differed only slightly between B and C. For all cohorts, disease activity decreased markedly from 0 to 6 months. In axSpA, disease activity at 24 months was highest in cohort A, where also remission and response rates were lowest. In PsA, remission rates at 6 and 12 months tended to be lowest in cohort A. Response rates were at all time points comparable across cohorts, and less between-cohort disease activity differences were seen at 24 months. CONCLUSION: Our findings indicate that over the past decades, clinicians have implemented more aggressive treatment strategies in spondyloarthritis. This was illustrated by shorter disease duration at treatment initiation, decreased retention rates and higher remission rates during recent years.
- Published
- 2022
42. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors:Data from the EuroSpA collaboration
- Author
-
Ørnbjerg, Lykke M., Linde, Louise, Georgiadis, Stylianos, Rasmussen, Simon H., Lindström, Ulf, Askling, Johan, Michelsen, Brigitte, Giuseppe, Daniela Di, Wallman, Johan K., Pavelka, Karel, Závada, Jakub, Nissen, Michael J., Jones, Gareth T., Relas, Heikki, Pirilä, Laura, Tomšič, Matija, Rotar, Ziga, Geirsson, Arni Jon, Gudbjornsson, Bjorn, Kristianslund, Eirik K., van sder Horst-Bruinsma, Irene, Loft, Anne Gitte, Laas, Karin, Iannone, Florenzo, Corrado, Addolorata, Ciurea, Adrian, Santos, Maria J., Santos, Helena, Codreanu, Catalin, Akkoc, Nurullah, Gunduz, Ozgul S., Glintborg, Bente, Østergaard, Mikkel, Hetland, Merete Lund, Ørnbjerg, Lykke M., Linde, Louise, Georgiadis, Stylianos, Rasmussen, Simon H., Lindström, Ulf, Askling, Johan, Michelsen, Brigitte, Giuseppe, Daniela Di, Wallman, Johan K., Pavelka, Karel, Závada, Jakub, Nissen, Michael J., Jones, Gareth T., Relas, Heikki, Pirilä, Laura, Tomšič, Matija, Rotar, Ziga, Geirsson, Arni Jon, Gudbjornsson, Bjorn, Kristianslund, Eirik K., van sder Horst-Bruinsma, Irene, Loft, Anne Gitte, Laas, Karin, Iannone, Florenzo, Corrado, Addolorata, Ciurea, Adrian, Santos, Maria J., Santos, Helena, Codreanu, Catalin, Akkoc, Nurullah, Gunduz, Ozgul S., Glintborg, Bente, Østergaard, Mikkel, and Hetland, Merete Lund
- Abstract
Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries. Methods: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data. Results: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26% and 51%, and the 12-month drug retention rate 65% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97–0.98), men vs. women: 1.88 (1.60–2.22), current vs. non-smoking: 0.76 (0.63–0.91), HLA-B27 positive vs. negative: 1.51 (1.20–1.91), TNF start year 2015–2018 vs. 2009–2014: 1.24 (1.06–1.45), CRP>10 vs. ≤10 mg/l: 1.49 (1.25–1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58–1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99–1.00) and 0.99 (0.99–1.99), respectively Conclusion: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations.
- Published
- 2022
43. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
- Author
-
Lauper, Kim, primary, Iudici, Michele, additional, Mongin, Denis, additional, Bergstra, Sytske Anne, additional, Choquette, Denis, additional, Codreanu, Catalin, additional, Cordtz, René, additional, De Cock, Diederik, additional, Dreyer, Lene, additional, Elkayam, Ori, additional, Hauge, Ellen-Margrethe, additional, Huschek, Doreen, additional, Hyrich, Kimme L, additional, Iannone, Florenzo, additional, Inanc, Nevsun, additional, Kearsley-Fleet, Lianne, additional, Kristianslund, Eirik Klami, additional, Kvien, Tore K, additional, Leeb, Burkhard F, additional, Lukina, Galina, additional, Nordström, Dan C, additional, Pavelka, Karel, additional, Pombo-Suarez, Manuel, additional, Rotar, Ziga, additional, Santos, Maria Jose, additional, Strangfeld, Anja, additional, Verschueren, Patrick, additional, Courvoisier, Delphine Sophie, additional, and Finckh, Axel, additional
- Published
- 2022
- Full Text
- View/download PDF
44. EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis
- Author
-
van Steenbergen, Hanna W, Aletaha, Daniel, Beaart-van de Voorde, Liesbeth J J, Brouwer, Elisabeth, Codreanu, Catalin, Combe, Bernard, Fonseca, João E, Hetland, Merete L, Humby, Frances, Kvien, Tore K, Niedermann, Karin, Nuño, Laura, Oliver, Sue, Rantapää-Dahlqvist, Solbritt, Raza, Karim, van Schaardenburg, Dirkjan, Schett, Georg, De Smet, Liesbeth, Szücs, Gabriella, Vencovský, Jirí, Wiland, Piotr, de Wit, Maarten, Landewé, Robert L, and van der Helm-van Mil, Annette H M
- Published
- 2017
- Full Text
- View/download PDF
45. After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries.
- Author
-
Pombo-Suarez, Manuel, Sanchez-Piedra, Carlos, Gómez-Reino, Juan, Lauper, Kim, Mongin, Denis, Iannone, Florenzo, Pavelka, Karel, Nordström, Dan C., Inanc, Nevsun, Codreanu, Catalin, Hyrich, Kimme L., Choquette, Denis, Strangfeld, Anja, Leeb, Burkhard F., Rotar, Ziga, Rodrigues, Ana, Kristianslund, Eirik Klami, Kvien, Tore K., Elkayam, Ori, and Lukina, Galina
- Published
- 2023
- Full Text
- View/download PDF
46. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis
- Author
-
Nissen, Michael, primary, Delcoigne, Bénédicte, additional, Di Giuseppe, Daniela, additional, Jacobsson, Lennart, additional, Hetland, Merete Lund, additional, Ciurea, Adrian, additional, Nekvindova, Lucie, additional, Iannone, Florenzo, additional, Akkoc, Nurullah, additional, Sokka-Isler, Tuulikki, additional, Fagerli, Karen Minde, additional, Santos, Maria Jose, additional, Codreanu, Catalin, additional, Pombo-Suarez, Manuel, additional, Rotar, Ziga, additional, Gudbjornsson, Bjorn, additional, van der Horst-Bruinsma, Irene, additional, Loft, Anne Gitte, additional, Möller, Burkhard, additional, Mann, Herman, additional, Conti, Fabrizio, additional, Yildirim Cetin, Gozde, additional, Relas, Heikki, additional, Michelsen, Brigitte, additional, Avila Ribeiro, Pedro, additional, Ionescu, Ruxandra, additional, Sanchez-Piedra, Carlos, additional, Tomsic, Matija, additional, Geirsson, Árni Jón, additional, Askling, Johan, additional, Glintborg, Bente, additional, and Lindström, Ulf, additional
- Published
- 2022
- Full Text
- View/download PDF
47. Predictors of ASDAS Inactive Disease in Axial Spondyloarthritis During Treatment with TNF-Inhibitors: Data from the Eurospa Collaboration
- Author
-
Ørnbjerg, Lykke M., primary, Linde, Louise, additional, Georgiadis, Stylianos, additional, Rasmussen, Simon H., additional, Lindström, Ulf, additional, Askling, Johan, additional, Michelsen, Brigitte, additional, Di Giuseppe, Daniela, additional, Wallman, Johan K., additional, Pavelka, Karel, additional, Závada, Jakub, additional, Nissen, Michael J., additional, Jones, Gareth T., additional, Relas, Heikki, additional, Pirilä, Laura, additional, Tomšič, Matija, additional, Rotar, Ziga, additional, Geirsson, Arni Jon, additional, Gudbjornsson, Bjorn, additional, Kristianslund, Eirik K., additional, van der Horst-Bruinsma, Irene E., additional, Loft, Anne Gitte, additional, Laas, Karin, additional, Iannone, Fiorenzo, additional, Corrado, Addolorata, additional, Ciurea, Adrian, additional, Santos, Maria J., additional, Santos, Helena, additional, Codreanu, Catalin, additional, Akkoc, Nurullah, additional, Gunduz, Ozgul S., additional, Glintborg, Bente, additional, Østergaard, Mikkel, additional, and Hetland, Merete Lund, additional
- Published
- 2022
- Full Text
- View/download PDF
48. European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response
- Author
-
Christiansen, Sara Nysom, primary, Ørnbjerg, Lykke Midtbøll, additional, Rasmussen, Simon Horskjær, additional, Loft, Anne Gitte, additional, Askling, Johan, additional, Iannone, Florenzo, additional, Zavada, Jakub, additional, Michelsen, Brigitte, additional, Nissen, Michael, additional, Onen, Fatos, additional, Santos, Maria Jose, additional, Pombo-Suarez, Manuel, additional, Relas, Heikki, additional, Macfarlane, Gary J, additional, Tomsic, Matija, additional, Codreanu, Catalin, additional, Gudbjornsson, Bjorn, additional, Van der Horst-Bruinsma, Irene, additional, Di Giuseppe, Daniela, additional, Glintborg, Bente, additional, Gremese, Elisa, additional, Pavelka, Karel, additional, Kristianslund, Eirik Klami, additional, Ciurea, Adrian, additional, Akkoc, Nurullah, additional, Barcelos, Anabela, additional, Sánchez-Piedra, Carlos, additional, Peltomaa, Ritva, additional, Jones, Gareth T, additional, Rotar, Ziga, additional, Ionescu, Ruxandra, additional, Grondal, Gerdur, additional, Van de Sande, Marleen G H, additional, Laas, Karin, additional, Østergaard, Mikkel, additional, and Hetland, Merete L, additional
- Published
- 2021
- Full Text
- View/download PDF
49. impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis.
- Author
-
Nissen, Michael, Delcoigne, Bénédicte, Giuseppe, Daniela Di, Jacobsson, Lennart, Hetland, Merete Lund, Ciurea, Adrian, Nekvindova, Lucie, Iannone, Florenzo, Akkoc, Nurullah, Sokka-Isler, Tuulikki, Fagerli, Karen Minde, Santos, Maria Jose, Codreanu, Catalin, Pombo-Suarez, Manuel, Rotar, Ziga, Gudbjornsson, Bjorn, van der Horst-Bruinsma, Irene, Loft, Anne Gitte, Möller, Burkhard, and Mann, Herman
- Subjects
CLINICAL drug trials ,REPORTING of diseases ,C-reactive protein ,COMBINATION drug therapy ,CONFIDENCE intervals ,META-analysis ,ANTI-inflammatory agents ,ANKYLOSIS ,SPONDYLOARTHROPATHIES ,ANTIRHEUMATIC agents ,SYNTHETIC drugs ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,PATIENT compliance ,LOGISTIC regression analysis ,ODDS ratio ,ARTHRITIS ,DISEASE remission ,EVALUATION - Abstract
Objectives Many axial spondylarthritis (axSpA) patients receive a conventional synthetic DMARD (csDMARD) in combination with a TNF inhibitor (TNFi). However, the value of this co-therapy remains unclear. The objectives were to describe the characteristics of axSpA patients initiating a first TNFi as monotherapy compared with co-therapy with csDMARD, to compare one-year TNFi retention and remission rates, and to explore the impact of peripheral arthritis. Methods Data was collected from 13 European registries. One-year outcomes included TNFi retention and hazard ratios (HR) for discontinuation with 95% CIs. Logistic regression was performed with adjusted odds ratios (OR) of achieving remission (Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP < 1.3 and/or BASDAI < 2) and stratified by treatment. Inter-registry heterogeneity was assessed using random-effect meta-analyses, combined results were presented when heterogeneity was not significant. Peripheral arthritis was defined as ≥1 swollen joint at baseline (=TNFi start). Results Amongst 24 171 axSpA patients, 32% received csDMARD co-therapy (range across countries: 13.5% to 71.2%). The co-therapy group had more baseline peripheral arthritis and higher CRP than the monotherapy group. One-year TNFi-retention rates (95% CI): 79% (78, 79%) for TNFi monotherapy vs 82% (81, 83%) with co-therapy (P < 0.001). Remission was obtained in 20% on monotherapy and 22% on co-therapy (P < 0.001); adjusted OR of 1.16 (1.07, 1.25). Remission rates at 12 months were similar in patients with/without peripheral arthritis. Conclusion This large European study of axial SpA patients showed similar one-year treatment outcomes for TNFi monotherapy and csDMARD co-therapy, although considerable heterogeneity across countries limited the identification of certain subgroups (e.g. peripheral arthritis) that may benefit from co-therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
50. European bio-naïve spondyloarthritis patients initiating TNFi: Time trends in baseline characteristics, treatment retention and response
- Author
-
Christiansen, Sara Nysom, Ørnbjerg, Lykke Midtbøll, Horskjær Rasmussen, Simon, Loft, Anne Gitte, Askling, Johan, Iannone, Florenzo, Zavada, Jakub, Michelsen, Brigitte, Nissen, Michael, Onen, Fato, Santos, Maria Jose, Pombo-Suarez, Manuel, Relas, Heikki, Macfarlane, Gary J, Tomsic, Matija, Codreanu, Catalin, Gudbjornsson, Bjorn, Van der Horst-Bruinsma, Irene, Di Giuseppe, Daniela, Glintborg, Bente, Gremese, Elisa, Pavelka, Karel, Kristianslund, Eirik Klami, Ciurea, Adrian, Akkoc, Nurullah, Barcelos, Anabela, Sánchez-Piedra, Carlo, Peltomaa, Ritva, Jones, Gareth T, Rotar, Ziga, Ionescu, Ruxandra, Grondal, Gerdur, Van de Sande, Marleen G H, Laas, Karin, Østergaard, Mikkel, Hetland, Merete L, Gremese, Elisa (ORCID:0000-0002-2248-1058), Christiansen, Sara Nysom, Ørnbjerg, Lykke Midtbøll, Horskjær Rasmussen, Simon, Loft, Anne Gitte, Askling, Johan, Iannone, Florenzo, Zavada, Jakub, Michelsen, Brigitte, Nissen, Michael, Onen, Fato, Santos, Maria Jose, Pombo-Suarez, Manuel, Relas, Heikki, Macfarlane, Gary J, Tomsic, Matija, Codreanu, Catalin, Gudbjornsson, Bjorn, Van der Horst-Bruinsma, Irene, Di Giuseppe, Daniela, Glintborg, Bente, Gremese, Elisa, Pavelka, Karel, Kristianslund, Eirik Klami, Ciurea, Adrian, Akkoc, Nurullah, Barcelos, Anabela, Sánchez-Piedra, Carlo, Peltomaa, Ritva, Jones, Gareth T, Rotar, Ziga, Ionescu, Ruxandra, Grondal, Gerdur, Van de Sande, Marleen G H, Laas, Karin, Østergaard, Mikkel, Hetland, Merete L, and Gremese, Elisa (ORCID:0000-0002-2248-1058)
- Abstract
Objectives To investigate time trends in baseline characteristics and retention, remission and response rates in bio-naive axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating TNF inhibitor (TNFi) treatment. Methods Prospectively collected data on bio-naive axSpA and PsA patients from routine care in 15 European countries were pooled. Three cohorts were defined according to year of TNFi initiation: A (1999-2008), B (2009-2014) and C (2015-2018). Retention, remission and response rates were assessed at 6, 12 and 24 months. Results In total, 27 149 axSpA and 17 446 PsA patients were included. Cohort A patients had longer disease duration compared with B and C. In axSpA, cohort A had the largest proportion of male and HLA-B27 positive patients. In PsA, baseline disease activity was highest in cohort A. Retention rates in axSpA/PsA were highest in cohort A and differed only slightly between B and C. For all cohorts, disease activity decreased markedly from 0 to 6 months. In axSpA, disease activity at 24 months was highest in cohort A, where also remission and response rates were lowest. In PsA, remission rates at 6 and 12 months tended to be lowest in cohort A. Response rates were at all time points comparable across cohorts, and less between-cohort disease activity differences were seen at 24 months. Conclusion Our findings indicate that over the past decades, clinicians have implemented more aggressive treatment strategies in spondyloarthritis. This was illustrated by shorter disease duration at treatment initiation, decreased retention rates and higher remission rates during recent years.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.